
Organocatalytic Conjugate Addition of Nitroalkanes to 3-Ylidene Oxindoles: A Stereocontrolled Diversity Oriented Route to Oxindole Derivatives

Arianna Quintavalla,*^{,†} Francesco Lanza,[†] Elisa Montroni,^{†,‡} Marco Lombardo,[†] and Claudio Trombini[†]

[†]Department of Chemistry "G. Ciamician", Alma Mater Studiorum, University of Bologna, Via Selmi, 2, I-40126 Bologna, Italy [‡]Consorzio Interuniversitario "CINMPIS", V. Orabona 4, 70125 Bari, Italy

Supporting Information

ABSTRACT: An efficient and highly enantioselective Michael addition of nitroalkanes to 3-ylidene oxindoles is described, mediated by thiourea-based bifunctional organocatalysts. The stereochemistry at C_{α} and C_{β} centers is perfectly controlled, and the intermediate C-3 enolate is trapped with a second Michael acceptor. The developed one-pot three-component consecutive reactions generate up to four contiguous stereocenters, including the C-3 all-carbon quaternary center, in a perfectly defined configuration. The conversion of the β -nitro oxindole into the corresponding β -amino derivative discloses synthetically useful transformations, exploitable to generate pharmaceutically attractive molecular targets.



INTRODUCTION

The oxindole scaffold characterizes a large number of natural and synthetic compounds with important biological activities^{1,2} (Figure 1).

Therefore, considerable efforts have been devoted to design strategies to synthesize these challenging structures.³ The potential medicinal significance of these enantiopure backbones has prompted the development of asymmetric approaches, by means of chiral metal catalysts⁴ and, more recently, organo-catalysts.⁵ A main challenge in these approaches is the construction of the chiral backbone often containing sequences of stereocenters, including quaternary centers.⁶ In particular, a chiral quaternary center at the 3-position of the oxindole ring is a structural feature of almost all these bioactive scaffolds. In the past few years a huge number of contributions has been published in this field. Currently, there are two⁷ main organocatalytic strategies to address the C-3 all-carbon quaternary stereocenter, which exploit the electrophilic or nucleophilic character of the selected oxindole substrate, respectively (Scheme 1).

The first strategy is based on the preliminary nucleophilic conjugate addition to exocyclic α,β -unsaturated oxindole followed by spirocyclization,^{8,9} as shown in Scheme 1, eq 1. Alternatively, the nucleophilicity of C-3 is exploited, typically starting from racemic C-3 monosubstituted derivatives¹⁰ (Scheme 1, eq 2a). Domino spiroannulations are again possible when an electrophilic function is present on the C-3 side chain¹¹ (Scheme 1, eq 2b). Spirocyclizations (Scheme 1, eqs 1 and 2b) are the most frequently exploited approaches, where the chirality generated in the first step controls the formation of the adjacent stereocenters. On the other hand, the reported intermolecular

additions^{10,12} (Scheme 1, eq 2a) bypass the generation of a stereolabile tertiary center at C-3, directly assembling the chiral quaternary center at this position. Since the conjugate addition shown in Scheme 1, eq 3 provides a poor control of the C-3 stereochemistry, there are very few studies of organocatalytic asymmetric intermolecular additions to the β -carbon of 3-ylidene oxindoles. Xiao and co-workers¹³ reported the conjugate addition of acetylacetone to 3-ylidene oxindoles, and using nitromethane as a Michael donor, the expected product was obtained in high yield and enantiocontrol at C_{av} but in almost identical amounts of the two diastereoisomers due to lack of control at C-3.

As part of our ongoing investigation into the stereoselective addition of nitroalkanes to α,β -unsaturated systems¹⁴ promoted by bifunctional thiourea-based organocatalysts,¹⁵ we set out to develop the Michael addition of nitroalkanes (1) to 3-ylidene oxindoles (2) to access highly stereoenriched C-3 β -nitro oxindoles (3) (Scheme 2, eq 1). Following a "diversity-oriented synthesis" (DOS)¹⁶ approach, we checked the opportunities offered by the adducts so generated to create structural diversification in chiral 3,3'-disubstituted oxindoles.


It is noteworthy that the C-3 β -nitro oxindole core was usually synthesized by exploiting conjugate additions to nitroalkenes^{4,5,8–11} (Scheme 2, eq 2). Very few authors^{8j,12a,13} explored the complementary reactivity between nitroalkanes and 3-ylidene oxindoles, which was exploited in our approach (Scheme 2, eq 1).

Received: September 22, 2013

но HO, NC CI 0= Mé Ho WAY-255348^{2a} NITD609^{2e} C MI-219^{2d} HO, H нс CONH₂ MeC N H но gelsemine^{3b} (-)-horsfiline^{3f} ĥ TMC-95A/B^{3a}


Figure 1. Representative natural and synthetic bioactive products containing the oxindole skeleton.

Scheme 1. Organocatalytic Strategies Employed To Asymmetrically Generate an All-Carbon Quaternary Stereocenter on the C-3 Oxindole Position^a



^aAbbreviations: Nu = nucleophilic site; E, E¹, E² = electrophilic sites; EWG = electron-withdrawing group; Y = generic substituent.

Scheme 2. Our Asymmetric Approach (Eq 1) to C-3 β -Nitro Oxindole Scaffolds in Comparison with the Most Investigated Approach in the Literature (Eq 2)




Article

RESULTS AND DISCUSSION

Initially we focused our attention on the addition of nitromethane (1a) to differently *N*-substituted (*E*)-ethyl 2-(2oxoindolin-3-ylidene)acetates (2a-c) by using the bifunctional *Cinchona*-derived organocatalyst I. As summarized in Table 1,

Table 1. N-Protecting Groups and Catalysts Screening in the Organocatalyzed Asymmetric Conjugate Addition of 1a to 3-Ylidene Oxindoles $(2a-c)^a$



^aReaction conditions: 2 (0.1 mmol), 1a (1 mmol), catalyst (10 mol %), dichloromethane (DCM, 0.15 mL), room temperature. ^bDetermined by ¹H NMR of the crude mixture. ^cDetermined by chiral stationary phase (CSP) HPLC of 3, isolated as a mixture of two C-3 epimers; ee values refer to the two C-3 epimers. ^dOpposite enantiomers were formed.

90

53/47

83/86^d

2

11

2c

IX

the employed conditions allowed us to perform reactions much more quickly than those reported by Xiao¹³ (90% yield after 15 h), and complete conversions were recorded within only 2 h with all of the substrates 2a-c (entries 1–3).

As expected, the diastereomeric ratio (dr) was very poor, even if associated with a high enantiomeric excess (ee) for both of the diastereoisomers. Since the best enantioselectivity was achieved for the *N*-Boc substrate 2c (entry 3), further optimization was performed on it. However, we were pleased to note that just slightly lower ees were obtained for unprotected starting material 2a (entry 1). This is a noteworthy result, since most of the reported reactions work well on N-protected substrates only. Other bifunctional organocatalysts (II–IX, Table 1) were tested in the model reaction on substrate 2c, and high conversions in short reaction times were invariably observed (entries 4-11). Diastereo- and enantioselectivity did not undergo significant changes when Cinchona-derived thioureas (II-V) and Takemoto's thiourea (VI) were used (entries 4-8). Significant lower ees were recorded employing Cinchona alkaloids VIII and IX (entries 10 and 11), and even worse results were obtained with particularly Jacobsen's thiourea VII (entry 9). The best results in terms of reaction rate and stereocontrol were obtained with catalysts I and VI; thus, further optimization was carried out using the lowcost, commercially available Takemoto thiourea VI.

The reaction conditions were deeply investigated to understand the effects of nitromethane equivalents, catalyst loading, solvent, and temperature on both the rate and the stereoselection of the process. Selected data are summarized in Table 2.

When the amount of nitromethane (entry 1) and the catalyst loading (entry 2) were individually lowered, and also when they were simultaneously decreased up to 2.5 equiv of 1a and 2.5 mol % of VI (entries 3 and 4), we still got excellent results. The reaction time increased but still was reasonable when 2 equiv of 1a and only 1 mol % of catalyst (entry 5) were used. Some solvents were also screened, without significant changes in the reaction performance. Finally we lowered the temperature (entries 6 and 7), but we did not observe any improvement in the diastereoselection. From these results we can infer that our reaction system did not allow a stereoselective C-3 protonation. Indeed the C3-H acidity of 3-alkylsubstituted oxindoles might be significantly influenced by the *N*-protecting group.¹⁷ Electron-withdrawing protecting groups increase the acidity of the C-3 position; for instance, the pK_a value of N-acetyloxindole is around 13. Hence, the N-Boc protection could favor a C-3 epimerization under our reaction conditions.¹¹

To expand the reaction scope, we applied our protocol to a variety of 3-ylidene oxindoles (2c-n), and we were delighted to find that the process tolerated different substitution patterns very well (Table 3). The employed conditions, representing the best balance of reaction rate and stereocontrol for the different substrates, were identified with 5 equiv of 1a and 5 mol % of catalyst VI. The reactions smoothly proceeded when the aromatic ring was decorated with both electron-withdrawing (entries 2–5) and electron-donating (entry 6) groups. In addition, the substituent position on the ring did not affect the efficiency of the process (cf. entries 2 and 4 and entries 3 and 5). The ethyl ester could be replaced by benzyl (entry 7) and *tert*-butyl (entry 8) esters. So far, good yields and excellent enantioselectivities (up to >99% ee) were reached for both diastereoisomers of the β -nitro indolin-2-ones (3c-j).

Significant changes, mainly in the enantiocontrol, were observed when, instead of the ester function, aromatic or aliphatic groups were located at the exocyclic double bond. For the phenyl derivative **3k** the ee dropped to 60% (Table 3, entry 9) and the addition of an electron-withdrawing substituent on the phenyl ring provided even worse results (entry 10). The last attempt was conducted on introducing an aliphatic group on the double bond; however, we obtained very poor ees and longer reaction times (entry 11). The latter data suggested that a crucial role for the enantioselectivity was played by the presence of an ester on the 3-ylidene oxindole. According to the dual activation model¹⁹ proposed by Takemoto^{19a} and Deng^{19b} and theoretical

Table 2. Optimization of the Reaction Conditions for the	Organocatalyzed Asymmetric Conjugate Addition of 1a to 3-Ylidene
Oxindole 2c ^a	

entry	amt of 1a (equiv)	amt of VI (mol %)	<i>T</i> (°C)	time (h)	conversn $(\%)^b$	dr ^b	ee (%) ^c
1	2.5	10	room temp	1	99	57/43	97/>99
2	10	1	room temp	1.5	99	52/48	>99/99
3	5	5	room temp	1	99	53/47	99/99
4	2.5	2.5	room temp	2	99	52/48	98/98
5	2	1	room temp	5.5	72	52/48	95/95
6	5	5	0	1.5	99	49/51	>99/>99
7	5	5	-20	120	72	47/53	>99/>99

^{*a*}Reaction conditions: **2c** (0.1 mmol), catalyst **VI**, DCM (0.15 mL). ^{*b*}Determined by ¹H NMR of the crude mixture. ^{*c*}Determined by CSP-HPLC of **3c**, isolated as a mixture of two C-3 epimers; ee values refer to the two C-3 epimers.

Table 3. Organocatalyzed Asymmetric Conjugate Addition of 1a to 3-Ylidene Oxindoles 2c-n^a

$R^{1} \xrightarrow[l]{l} \\ R^{1} \xrightarrow[l]{l} \\ R^{1} \xrightarrow[l]{l} \\ N_{Boc} \\ N \\ DCM/rt \\ N \\ DCM/rt \\ N \\ Boc \\ N \\ $										
			2c-n			3c-n				
entry	substrate	\mathbb{R}^1	\mathbb{R}^2	R ³	product	time (h)	yield (%) ^b	dr ^c	ee $(\%)^d$	
1	2c	Н	CO ₂ Et	Н	3c	1	80	53/47	99/99	
2	2d	5-Cl	CO ₂ Et	Н	3d	3.5	83	60/40	>99/>99	
3	2e	5-Br	CO ₂ Et	Н	3e	3.5	72	53/47	>99/>99	
4	2f	6-Cl	CO ₂ Et	Н	3f	1.5	92	56/44	98/98	
5	2g	7-Br	CO ₂ Et	Н	3g	1	82	59/41	95/94	
6	2h	5-OMe	CO ₂ Et	Н	3h	1	89	55/45	>99/>99	
7	2i	Н	CO ₂ Bn	Н	3i	2	72	55/45	>99/>99	
8	2j	Н	CO ₂ tBu	Н	3j	2	99	57/43	>99/>99	
9	2k	Н	Ph	Н	3k	2	52	59/41	60/64	
10	21	Н	pNO_2Ph	Н	31	2	98	60/40	31/33	
11	2m	Н	tBu	Н	3m	26	62	69/31	26/29	
12	2n	Н	CO ₂ Et	Me	3n	2	57	60/40	94/92	

^{*a*}Reaction conditions: **2** (0.1 mmol), **1a** (0.5 mmol), catalyst **VI** (5 mol %), DCM (0.15 mL), room temperature. ^{*b*}Yield of isolated product after flash chromatography. ^{*c*}Determined by ¹H NMR of the crude mixture. ^{*d*}Determined by CSP-HPLC of products **3**, isolated as a mixture of two C-3 epimers; ee values refer to the two C-3 epimers.

Table 4. Organocatalyzed Asymmetric Conjugate Addition of Nitroalkanes 1a-f to 3-Ylidene Oxindole $2c^a$

		1a-f →o DCM/0°C	$\begin{array}{c} \text{EtOOC} \\ H_3 \\ NO_2 \\$	+ $H_{3} = 0$ Boc $A = 0$ A = 0 A = 0 A = 0 B = 0 B = 0 B = 0		
entry	nitroalkane	product	syn- 4b-e time (h)	yield (%) ^b	anti/syn ^c	ee anti $(\%)^d$
,		1	time (ii)		unu/syn	
1^e	$MeNO_2$ (1a)	3c	1	80		99/99
2^e	$EtNO_2$ (1b)	4b	2	78	76/24	97/98
3^f	$EtNO_2$ (1b)	4b	48	73	99/1	>99/>99
4	$EtNO_2$ (1b)	4b	3	71	95/5	>99/>99
5	$n Pr NO_2$ (1c)	4c	7	76	92/8	>99/>99
6	$MeO_2C(CH_2)_3NO_2$ (1d)	4d	4	83	91/9	>99/>99
7	$Ph(CH_2)_2NO_2$ (1e)	4e	4	72	90/10	>99/>99
8	$i Pr NO_2$ (1f)	4f	144	traces		

^{*a*}Reaction conditions: **2c** (0.1 mmol), **1** (0.5 mmol), catalyst **VI** (10 mol %), DCM (0.15 mL), 0 °C. ^{*b*}Yield of isolated product after flash chromatography. ^{*c*}Determined by CSP-HPLC of the crude mixture; the stereochemical notations *anti* and *syn* refer to the $C_{\alpha}-C_{\beta}$ relationship. ^{*d*}Determined by CSP-HPLC of the products, isolated as a mixture of two C-3 epimers; ee values refer to the two C-3 epimers. ^{*c*}Reaction performed at room temperature with 5 mol % of **VI**. ^{*f*}Reaction performed at -10 °C.

calculations performed by Papai,^{19c} the bifunctional organocatalyst should simultaneously activate both Michael donor and acceptor, thus controlling the approach of the nitroalkane to the 3-ylidene oxindole. The oxindole reasonably interacts with the thiourea moiety via multiple hydrogen bonds, enhancing the electrophilicity of the reacting carbon center. Concurrently, the


nitro compound coordinates to the tertiary amine group. The poor enantiocontrol observed when the methyleneindolinone was directly connected to an aryl or alkyl group suggests that the ester moiety affects the coordination between catalyst and substrate, enabling a high enantiocontrol. On the other hand, the interaction between the *N*-Boc carboxyl group and the catalyst, identified as crucial by many authors,^{8j,9f,10e,f,k,n,11d,f} in our system seems to be present but not strictly necessary, as evidenced by the small differences in enantioselectivity recorded for substrates 2a-c (Table 1, entries 1–3).

The substrate scope was also extended to the challenging construction of a quaternary stereocenter on the C_{α} position. For this purpose we applied our protocol to substrate **2n**, characterized by a tetrasubstituted exocyclic double bond (Table 3, entry 12). Once again, the reaction quickly provided the desired product with high ees for both diastereoisomers.

The next step in our investigation was to explore the use of higher nitroalkanes as Michael donors (Table 4), with the aim of introducing a further stereocenter and approaching the structural complexity of bioactive oxindoles.

We first applied the same conditions optimized for nitromethane 1a (Table 4, entry 1). Nitroethane 1b quickly provided the desired product 4b in good yield and excellent stereocontrol at C_{α} but with modest control of the C_{β} stereochemistry (entry 2). We tried to improve the dr by lowering the temperature, and pleasingly, the diastereocontrol at -10 °C was almost complete (entry 3). However, the reaction time was much longer (48 h), so that the best trade-off between reactivity and stereoselectivity was reached by employing 10 mol % of catalyst at 0 °C. After 3 h 4b was obtained in good yield and dr and high ees for each diastereoisomer (entry 4). The protocol was successfully applied to nitroalkanes 1c-e (entries 5-7). Only the isopropyl derivative 1f did not afford the corresponding product (entry 8); this was probably due to the great steric compression at the α -nitro position. Data presented in Table 4 showed that the configurations of the two stereocenters directly generated in the conjugate addition were highly defined, while the C-3 configuration was, as usual, out of control. With the aim of introducing a quaternary and two tertiary adjacent stereocenters on the oxindole scaffold, we extended the addition of nitroethane 1b to substrate 2n (Scheme 3).

Scheme 3. Organocatalytic Protocol Employed To Stereoselectively Introduce a Quaternary and Two Tertiary Adjacent Stereocenters



The adduct **5** was obtained in good yield and high ee, and surprisingly, in this case the two C-3 epimers were not equally present (dr = 85/15). A possible explanation could be that the steric crowding and the substituent distribution on the adjacent stereocenters partially affect the C-3 configuration.

Summarizing the first part of this study, we developed an asymmetric organocatalytic protocol for the conjugate addition of nitroalkanes to 3-ylidene oxindoles, which efficiently provided substituted β -nitro indolin-2-ones in good yields and excellent enantioselectivities. Indeed, up to three stereocenters were generated one pot, two of them with high stereocontrol.

Although it was not possible to control the absolute configuration of the third stereocenter, this limitation can be turned into an opportunity if we react the β -nitro oxindole 4 with an electrophile, with the aim of building up an all-carbon C-3 quaternary stereocenter increasing the structural complexity (Scheme 2, eq 1). With respect to the previously reported strategies, that employ simple C-3 racemic substrates^{4a,c,e,5,10} (Scheme 1, eq 2a), our approach consists of reacting a pair of diastereoisomers (Scheme 1, eq 3). In this perspective, the β -nitro indolin-2-one scaffold 4 could represent a useful precursor for the asymmetric synthesis of 3,3'-disubstituted oxindoles with more substitution variants.

The first attempts were made by exploiting *N*-phenyl-maleimide,²⁰ 1,1-bis(benzenesulfonyl)ethylene²¹ and *trans-β*-nitrostyrene²² as electrophiles, in the presence of the same thiourea catalyst used for the preliminary Michael addition. As shown in Scheme 4, the reaction with *N*-phenylmaleimide proceeded smoothly, affording product **6** as a single stereoisomer in good yield. In this one-pot three-component tandem reaction four contiguous stereocenters, including the desired C-3 all-carbon quaternary center, were enantioselectively generated.


To introduce structural diversity, the reactivity of 4b was also tested in the Michael addition to 1,1-bis(benzenesulfonyl)ethylene (Scheme 4). Compound 7, featuring three adjacent stereocenters, was efficiently isolated with excellent stereoenrichment. With regard to the organocatalyzed conjugate addition of 3-substituted racemic oxindole derivatives to vinyl sulfones, it is known that good stereocontrol is possible only if an aryl substituent on C-3 is present, while 3-alkyl oxindoles generally afford the corresponding adducts in low yields and poor enantioselectivity. For this reason, Lu and co-workers²¹ ' and Kim and co-workers^{21b} were forced to develop specifically modified organocatalysts. In our case, thanks to the matched induction of pre-existing stereocenters and catalyst, the asymmetric Michael reaction smoothly proceeded on 3-alkyl oxindole 4b with the readily available Takemoto catalyst VI.

The last application of the hydrogen-bond catalysis involved the addition of **4b** to *trans-\beta*-nitrostyrene (Scheme 5), further confirming the versatility of the β -nitro indolin-2-one scaffold as a synthetic precursor of optically active 3,3'-disubstituted oxindoles.


One of the advantages of the proposed one-pot tandem reactions was that a single catalyst sequentially promoted two different transformations, so that the addition of other catalysts was not necessary. However, to further expand the opportunities of structural diversification, we explored a second activation mode employing covalent amino catalysis for the reaction of **4b** with 2-cyclohexen-1-one^{10p,11a} and with crotonaldehyde.^{8a,c,d,10j,11c,d} As depicted in Scheme 6, the thiourea **VI** was easily removed by means of an acidic workup, allowing us to carry out the subsequent Michael reaction directly on the crude reaction mixture containing **4b**.

Primary amine **X** and secondary amine **XI** represent the matched catalysts for the addition of *anti*-**4b** to cyclohexenone and crotonaldehyde, respectively, affording the corresponding products **9** and **10** in good yields. Once again, 3,3'-disubstituted oxindoles bearing four contiguous stereocenters were obtained with good to excellent stereocontrol.

A notable synthetic application of the β -nitro oxindole scaffold lies in its easy conversion to the corresponding β -amino motif recognized in many bioactive compounds.^{1–3} As depicted in Scheme 7, on reduction with Raney nickel of the β -nitro indolin-2-one **4b**, we quantitatively obtained the expected β -amino indolin-2-one **11**. Scheme 4. One-Pot Three-Component Tandem Reactions To Access 3,3'-Disubstituted Oxindoles 6 and 7




Scheme 5. One-Pot Three-Component Tandem Reaction To Access 3,3'-Disubstituted Oxindole 8




Looking for the best reaction conditions, we tried also palladium on carbon as a reducing agent and, interestingly, the pair of observed products was different from those obtained using Raney nickel. A careful analysis of the HPLC-MS and NMR spectra allowed us to establish that the palladium catalyst partially reduces the β -nitro oxindole 4b to the corresponding β -hydroxylamino oxindole 12²³ (Scheme 7). As expected, the β -amino and the β -hydroxylamino derivatives were both isolated as mixtures of two C-3 epimers (11a,b and 12a,b, respectively) but, interestingly, when subjected to basic conditions they converged to a single stereoisomer (Scheme 7). As previously mentioned about compound 5, the C-3 configuration could be affected by the stereochemical features and the ability to form specific interactions of the substituents on C_{α} and C_{β} . In this case, the greater thermodynamic stability of 11a and 12a acts as a driving force in the base-promoted stereoconvergent C-3 epimerization.

Scheme 7. Reducing Agent Dependent Transformations of β -Nitro Oxindole 4b into β -Amino 11 and β -Hydroxylamino 12 Oxindoles. Stereoconvergent Base-Promoted C-3 Epimerization of β -Amino and β -Hydroxylamino Derivatives




At last we remark the usefulness of the asymmetric organocatalytic conjugate addition of nitroalkanes to 3-ylidene oxindoles reported here in the synthesis of enantioenriched oxindole and indoline derivatives, potentially exploitable in drug discovery. For example, the optically active conjugate adduct

Scheme 6. Sequential Synthesis of 3,3'-Disubstituted Oxindoles 9 and 10



anti-4b (>99% ee) was first reduced and then cyclized to compound 13, featuring a core structure similar to those of many important natural products²⁴ (Scheme 8). The absolute

Scheme 8. Synthetic Elaborations on the Optically Active Conjugate Adduct *anti*-4b To Obtain the Stereochemically Different Compounds 13 and 14, Featuring a Natural Core Structure



configuration of compound 13 has been determined by theoretical calculation of its electronic circular dichroism (ECD) spectrum and of its optical rotation (OR), using the TD-DFT method (see the Supporting Information).

The possibility of creating stereochemically different scaffolds starting from the same substrate could be synthetically very useful, providing a platform of diastereomeric derivatives to better evaluate the effect of relative stereochemistry on bioactivity. With this aim, exploiting the acidity on the C_{β} position, we subjected *anti*-4b to basic conditions (1,5-diazabicyclo[5.4.0]undec-5-ene, DBU, 30 mol %) and *syn*-4b was isolated in good yield without compromising the optical purity. The previously described reductive protocol²⁵ allowed us to obtain product 14, characterized by a relative stereochemistry different from that of compound 13. Thus, the C_{α} absolute configuration, controlled by the chiral thiourea during the conjugate addition, is the only one that remains unchanged, while the stereochemistry at the other centers can be manipulated by means of stereoconvergent transformations, depending on the desired target molecule.

CONCLUSION

Even though asymmetric processes applied to indoles, oxindoles, and isatins seem to represent a mature field in organocatalysis, we demonstrated that still a number of useful reactions and applications can be disclosed. We carefully examined the Michael addition of nitroalkanes to 3-ylidene oxindoles and found optimized conditions to perfectly control the stereochemistry at C_{α} and C_{β} centers. Under our reaction conditions we had no chance to stereodefine the C-3 position; however, when the generated intermediate enolate was trapped with a second Michael acceptor, an all-carbon quaternary stereocenter was formed in a perfectly defined configuration. The conversion of the β -nitro oxindole adduct into the corresponding β -amino derivative disclosed intriguing and synthetically useful transformations, such as stereoconvergent processes and stereoselective base-promoted isomerizations. Considering the number of substrates examined and the number of synthetic transformations they were subjected to, we believe to have demonstrated the

synthetic value of the developed asymmetric Michael addition of nitroalkanes to 3-ylidene oxindoles, complementary to the most widely studied reactions present in the literature.

EXPERIMENTAL SECTION

Materials. All of the chemicals were used as received. Catalysts I-V were known and prepared according to the literature procedures.²⁶ Compounds 2a,²⁷ 2b,c,²⁸ 2d-f,h,^{11f} 2i,^{9f} 2j,k,^{9a,d} 2l,^{9b} and $1e^{29}$ were known and prepared according to the literature procedures. **Characterization of Compounds.** ¹H and ¹³C NMR spectra were

recorded on a 200 or 400 NMR instrument with a 5 mm probe. All chemical shifts have been quoted relative to deuterated solvent signals: chemical shifts (δ) are reported in ppm, and coupling constants (\overline{J}) are reported in Hz; HPLC-MS analysis was performed using an HPLC system coupled with a single-quadrupole mass spectrometer. A ZOBRAX-Eclipse XDB-C8 column was employed for the chromatographic separation: mobile phase H_2O/CH_3CN , gradient from 30% to 80% of CH₂CN in 8 min, 80% of CH₂CN until 25 min, 0.4 mL min⁻¹. Mass spectrometric detection was performed in full-scan mode from m/z 50 to 2600: scan time 0.1 s in positive ion mode, ESI spray voltage 4500 V, nitrogen gas 35 psi, drying gas flow 11.5 mL min⁻¹, fragmentor voltage 20 V. CSP-HPLC analyses were performed using hexane/ 2-propanol (n-Hex/IPA) mixtures. Flash chromatography was carried out using Merck silica gel 60 (230-400 mesh particle size). Thin-layer chromatography was performed on Merck 60 F254. The $[\alpha]_D^{25}$ values and the *major* enantiomers in the following characterization have been defined with respect to the products obtained with catalyst VI.

Synthesis of (E)-tert-Butyl 7-Bromo-3-(2-ethoxy-2-oxoethylidene)-2-oxoindoline-1-carboxylate (2g). Ethyl 2-(triphenylphosphoranylidene)acetate (1.2 mmol) was added to a solution of 7-bromoindoline-2,3-dione (1 mmol, 226 mg) in DCM (4 mL). The reaction mixture was stirred at room temperature overnight. After the reaction was complete, the solvent was removed under reduced pressure. The crude mixture was dissolved in THF (5 mL), DMAP (4-dimethylaminopyridine, 5 mol %) was added to the solution, and finally, Boc2O (di-tert-butyl dicarbonate, 1.1 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. Then the solvent was removed under reduced pressure and the product was purified by flash chromatography on silica gel (cyclohexane/ ethyl acetate 9/1): 95% yield (376 mg), crystalline solid (mp 73–77 °C); ¹H NMR (400 MHz, CDCl₃) δ 8.66 (dd, J = 7.9 and 1.1 Hz, 1H), 7.59 (dd, J = 8.1 and 1.1 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.94 (s, 1H), 4.34 (q, J = 7.1Hz, 2H), 1.66 (s, 9H), 1.38 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) & 14.1, 27.7, 61.5, 85.8, 106.7, 123.4, 124.6, 125.6, 127.5, 136.2, 137.1, 140.8, 147.6, 164.9, 166.3; HPLC-MS (ESI) $t_r = 12.7 \text{ min}; [M + Na]^+$ 418.2 m/z, $[2M + Na]^+$ 813.2 m/z, 817.2 m/z. Anal. Calcd for C₁₇H₁₈BrNO₅ (395.04): C, 51.53; H, 4.58; N, 3.53. Found: C, 51.37; H, 4.56; N. 3.54.

Synthesis of (E)-tert-Butyl 3-(2,2-Dimethylpropylidene)-2oxoindoline-1-carboxylate (2m). Pivalaldehyde (1.2 mmol) was added to a solution of indolin-2-one (1 mmol, 133 mg) in EtOH (5 mL), finally piperidine (10 mol %) was added. The reaction was refluxed for 1.5 h, then it was cooled to room temperature and the solvent was removed under reduced pressure. The product was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 8/2). (E)-3-(2,2-Dimethylpropylidene)indolin-2-one was dissolved in THF (5 mL), and then DMAP (5 mol %) was added and finally Boc₂O (1.1 mmol). The reaction mixture was stirred at room temperature for 1 h. After the reaction was complete, the solvent was removed under reduced pressure and the product was purified by flash chromatography on silica gel (cyclohexane/ ethyl acetate 9/1): 97% yield (292 mg); crystalline solid (mp 82–86 °C); ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 7.8 Hz, 1H), 7.78–7.71 (m, 1H), 7.36–7.29 (m, 1H), 7.25 (s, 1H), 7.17 (td, J = 7.7 and 1.2 Hz, 1H), 1.65 (s, 9H), 1.39 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 28.1, 29.1, 32.7, 84.0, 115.0, 120.9, 123.5, 125.5, 126.0, 128.9, 140.0, 149.3, 154.3, 167.0; HPLC-MS (ESI) $t_r = 13.4 \text{ min}; [2M + Na]^+ = 625.4 \text{ } m/z$. Anal. Calcd for $C_{18}H_{23}NO_3$ (301.17): C, 71.73; H, 7.69; N, 4.65. Found: C, 71.61; H, 7.71; N, 4.65.

Synthesis of (*E*)-tert-Butyl 3-(1-Ethoxy-1-oxopropan-2-ylidene)-2-oxoindoline-1-carboxylate (2n). DMAP (5 mol %) was added to a solution of indoline-2,3-dione (1 mmol, 147 mg) in THF

(5 mL); then Boc₂O (1.1 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. After the reaction was complete, the solvent was removed under reduced pressure. The crude mixture was dissolved in DCM (4 mL), and ethyl 2-(triphenylphosphoranylidene)-propanoate (1.2 mmol) was added. The reaction mixture was stirred at room temperature overnight. Then the solvent was removed under reduced pressure and the product was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 9/1): 50% yield (166 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 8.7 Hz, 1H), 7.36–7.29 (m, 2H), 7.09 (t, *J* = 7.7 Hz, 1H), 4.43 (q, *J* = 7.1 Hz, 2H), 2.63 (s, 3H), 1.66 (s, 9H), 1.39 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 17.1, 28.1, 30.9, 62.0, 84.4, 114.9, 120.7, 122.0, 123.4, 123.9, 129.9, 138.8, 141.8, 149.2, 165.7, 169.2; HPLC-MS (ESI) *t*_r = 11.7 min; [M + Na]⁺ = 354.2 *m*/*z*, [2M + Na]⁺ = 685.5 *m*/*z*. Anal. Calcd for C₁₈H₂₁NO₅ (331.14): C, 65.24; H, 6.39; N, 4.23. Found: C, 65.22; H, 6.37; N, 4.22.

General Procedure for the Organocatalyzed Michael Addition of Nitroalkanes 1 to 3-Ylidene Oxindoles 2. The 3ylidene oxindole (0.1 mmol) was added to a solution of catalyst (5 or 10 mol %) in DCM (0.15 mL), and then nitroalkane (0.5 mmol) was added at room temperature or at 0 °C. The mixture was stirred at the same temperature, and the conversion was monitored by TLC and ¹H NMR. The crude mixture of the reactions performed at room temperature was directly purified by flash chromatography on silica gel (cyclohexane/ ethyl acetate 85/15). The crude mixture of the reactions performed at 0° C was quenched at the same temperature with 2 mL of HCl (1 N) and extracted with DCM $(3 \times 2 \text{ mL})$. The organic phases were collected and dried over Na₂SO₄, the solvent was evaporated under reduced pressure without heating, and the product was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 85/15). Before CSP-HPLC analysis, the purified product (0.04 mmol) (and, when necessary, the crude reaction mixture) was deprotected using 18 equiv of trifluoroacetic acid (TFA) in 0.4 mL of DCM. After 45 min the reaction was quenched with 2 mL of a 0.1 M solution of phosphate buffer (pH 7) and the aqueous phase was extracted with DCM (2×2 mL). The organic phases were collected and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the corresponding N-deprotected β -nitro oxindole was obtained pure and directly injected into CSP-HPLC.

3-((R)-1-Ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline (3a): mixture of two diastereoisomers; 85% yield (24 mg), oil; ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3) \delta 7.93 \text{ (bs, 2H)}, 7.34-7.20 \text{ (m, 3H)}, 7.17 \text{ (d, } J = 7.5 \text{ (m, 3H)})$ Hz, 1H), 7.12-7.01 (m, 2H), 6.91 (d, J = 7.8 Hz, 2H), 4.99 (dd, J = 14.5 and 9.4 Hz, 1H), 4.78 (dd, J = 14.8 and 8.9 Hz, 1H), 4.46 (m, 2H), 4.29-4.14 (m, 4H), 4.14–4.07 (m, 1H), 4.04 (m, 1H), 3.99–3.91 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, $CDCl_3$ δ 13.8, 13.9, 43.0, 43.3, 45.0, 45.1, 62.1, 62.2, 72.0, 72.3, 110.3, 122.9, 123.0, 124.3, 124.4, 124.8, 125.0, 129.2, 129.3, 141.3, 141.6, 169.1, 169.8, 176.5, 176.8; HPLC-MS (ESI) $t_r = 6.4 \text{ min}, 6.8 \text{ min}; [M + H]^+ =$ 279.2 m/z, $[M + Na]^+ = 301.2 m/z$. Anal. Calcd for $C_{13}H_{14}N_2O_5$ (278.09): C, 56.11; H, 5.07; N, 10.07. Found: C, 55.91; H, 5.09; N, 10.04. CSP-HPLC: OJ 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 20 min, 80/20 up to 60 min; flow rate 0.5 mL/min at 40 °C; λ 214 nm; t_r (isomer A) = 38.5 min (major), 44.8 min (minor); t_r (isomer B) = 42.7 min (major), 53.8 min (minor).

(2R)-Ethyl 2-(1-benzyl-2-oxoindolin-3-yl)-3-nitropropanoate (3b): mixture of two diastereoisomers; 86% yield (32 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.16 (m, 14H), 7.10-7.01 (m, 2H), 6.84-6.72 (m, 2H), 5.03–4.88 (m, 5H), 4.80 (dd, J = 14.8 and 8.9 Hz, 1H), 4.52-4.37 (m, 2H), 4.24-4.04 (m, 6H), 4.01 (d, J = 3.7 Hz, 2H), 1.17 $(t, J = 7.1 \text{ Hz}, 3\text{H}), 1.08 (t, J = 7.1 \text{ Hz}, 3\text{H}); {}^{13}\text{C} \text{ NMR} (100 \text{ MHz}, 100 \text{ MHz})$ $CDCl_3$ δ 13.7, 13.8, 43.2, 43.4, 44.09, 44.11, 44.5, 44.6, 62.0, 62.1, 72.10, 72.41, 109.5, 122.9, 123.0, 124.0, 124.1, 124.3, 124.5, 127.4, 127.5, 127.88, 127.91, 128.86, 128.87, 129.0, 129.2, 135.40, 135.42, 143.4, 143.6, 169.2, 169.7, 174.4, 174.6; HPLC-MS (ESI) *t*_r = 9.5 min, 9.8 min; $[M + H]^+ = 369.2 m/z$, $[M + Na]^+ = 391.2 m/z$. Anal. Calcd for C₂₀H₂₀N₂O₅ (368.14): C, 65.21; H, 5.47; N, 7.60. Found: C, 65.06; H, 5.47; N, 7.61. CSP-HPLC: IC 90/10 n-Hex/IPA for 10 min, then up to 85/15 in 5 min, 85:15 up to 80 min; flow rate 0.5 mL/min at room temperature; λ 254 nm. t_r (isomer A) = 56.1 min (major), 71.0 min (minor); t_r (isomer B) = 61.2 min (major), 73.6 min (minor).

tert-Butyl 3-((*R*)-1-*ethoxy-3-nitro-1-oxopropan-2-yl*)-2-*oxoindo-line-1-carboxylate* (3*c*): mixture of two diastereoisomers; 80% yield (30 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (dd, *J* = 8.4 and 2.8 Hz, 2H), 7.41–7.33 (m, 2H), 7.29–7.14 (m, 4H), 5.01 (dd, *J* = 14.4 and 9.3 Hz, 1H), 4.84 (dd, *J* = 14.9 and 8.1 Hz, 1H), 4.64 (dd, *J* = 14.8 and 5.8 Hz, 1H), 4.40 (dd, *J* = 14.4 and 5.0 Hz, 1H), 4.23–4.06 (m, 6H), 4.04 (d, *J* = 3.8 Hz, 1H), 3.99 (d, *J* = 3.1 Hz, 1H), 1.65 (s, 18H), 1.18 (t, *J* = 7.1 Hz, 3H), 1.13 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 13.8, 28.0, 43.7, 43.9, 45.0, 45.4, 62.2, 62.3, 72.3, 72.4, 84.9, 85.0, 115.3, 115.4, 123.2, 123.5, 123.6, 123.7, 124.7, 124.8, 129.2, 129.5, 140.3, 140.6, 148.77, 148.76, 168.7, 169.2, 172.7, 173.4; HPLC-MS (ESI) *t*_r = 9.9 min, 10.0 min; [M + Na]⁺ = 401.3 *m/z*. Anal. Calcd for C₁₈H₂₂N₂O₇ (378.14): C, 57.14; H, 5.86; N, 7.40. Found: C, 57.02; H, 5.85; N, 7.39.

3-((*R*)-1-Ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers; CSP-HPLC: OJ 90/10 *n*-Hex/IPA for 10 min, then up to 80/20 in 20 min, 80/20 up to 70 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 43.2 min (major), 51.8 min (minor); t_r (isomer B) = 49.5 min (major), 63.9 min (minor).

tert-Butyl 5-*chloro-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline-1-carboxylate* (**3***d*): mixture of two diastereoisomers; 83% yield (34 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 5.1 Hz, 1H), 7.83 (d, *J* = 5.2 Hz, 1H), 7.38–7.31 (m, 2H), 7.24–7.20 (m, 2H), 5.00 (dd, *J* = 14.4 and 9.0 Hz, 1H), 4.91 (dd, *J* = 14.8 and 7.3 Hz, 1H), 4.78 (dd, *J* = 14.8 and 6.6 Hz, 1H), 4.46 (dd, *J* = 14.4 and 5.2 Hz, 1H), 4.22–4.03 (m, 6H), 4.00 (d, *J* = 4.3 Hz, 1H), 3.93 (d, *J* = 3.0 Hz, 1H), 1.64 (s, 18H), 1.22–1.09 (m, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 13.68, 13.73, 28.0, 43.7, 44.0, 44.7, 45.2, 62.4, 62.5, 72.2, 72.6, 85.2, 85.3, 116.6, 116.7, 123.7, 123.9, 125.1, 125.8, 129.2, 129.5, 130.2, 130.3, 138.9, 139.1, 148.6, 168.4, 168.6, 171.9, 172.8; HPLC-MS (ESI) *t*_r = 10.7 min; [M + Na]⁺ = 435.2, 437.3 *m/z*, [M + K]⁺ = 451.2 *m/z*, [2M + Na]⁺ = 847.4 *m/z*. Anal. Calcd for C₁₈H₂₁ClN₂O₇ (412.10): C, 52.37; H, 5.13; N, 6.79. Found: C, 52.21; H, 5.14; N, 6.78.

5-*Chloro-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline:* mixture of two diastereoisomers, gun; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (bs, 2H), 7.52–7.48 (m, 1H), 7.33–7.16 (m, 3H), 6.92–6.76 (m, 2H), 4.99 (dd, *J* = 14.4 and 9.0 Hz, 1H), 4.84 (dd, *J* = 14.7 and 8.2 Hz, 1H), 4.65–4.55 (m, 1H), 4.52 (dd, *J* = 14.5 and 4.9 Hz, 1H), 4.40 (m, 1H), 4.27–4.16 (m, 3H), 4.12–4.05 (m, 2H), 4.02–3.87 (m, 2H), 1.31–1.15 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 13.9, 43.1, 43.3, 44.8, 44.9, 62.3, 62.4, 72.1, 72.2, 111.0, 111.1, 124.5, 124.7, 124.9, 124.9, 126.8, 128.0, 128.4, 129.1, 129.3, 129.5, 139.7, 139.9, 168.9, 169.3, 176.0; HPLC-MS (ESI) *t_r* = 7.5 min, 7.6 min; [M + H]⁺= 313.1 *m/z*, [M + Na]⁺= 335.1 *m/z*. Anal. Calcd for C₁₃H₁₃ClN₂O₅ (312.05): C, 49.93; H, 4.19; N, 8.96. Found: C, 49.89; H, 4.20; N, 8.94. CSP-HPLC: IC 90/10 *n*-Hex/IPA up to 50 min; flow rate 0.6 mL/min at room temperature; λ 214 nm; *t_r*(isomer A) = 31.4 min (major), 39.7 min (minor); *t_r*(isomer B) = 44.2 min (minor), 45.9 min (major).

tertButyl 5-bromo-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2oxoindoline-1-carboxylate (**3e**): mixture of two diastereoisomers; 72% yield (33 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.82–7.76 (m, 2H), 7.53–7.45 (m, 2H), 7.40–7.32 (m, 2H), 5.00 (dd, *J* = 14.4 and 9.0 Hz, 1H), 4.91 (dd, *J* = 14.8 and 7.3 Hz, 1H), 4.80 (dd, *J* = 14.8 and 6.6 Hz, 1H), 4.46 (dd, *J* = 14.5 and 5.1 Hz, 1H), 4.24–4.02 (m, 6H), 4.00 (d, *J* = 4.3 Hz, 1H), 3.93 (d, *J* = 3.0 Hz, 1H), 1.64 (s, 18H), 1.22–1.09 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 13.7, 28.0, 43.8, 44.1, 44.7, 45.1, 62.4, 62.5, 72.2, 72.6, 85.2, 85.4, 117.0, 117.0, 117.6, 117.7, 125.5, 126.2, 126.5, 126.7, 132.1, 132.5, 139.4, 139.6, 148.6, 168.4, 168.6, 171.8, 172.7; HPLC-MS (ESI) *t*_r = 10.9 min; [M + Na]⁺= 479.2, 481.1 *m/z*. Anal. Calcd for C₁₈H₂₁BrN₂O₇ (456.05): C, 47.28; H, 4.63; N, 6.13. Found: C, 47.13; H, 4.61; N, 6.11.

5-Bromo-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (bs, 2H), 7.45–7.38 (m, 2H), 7.38–7.29 (m, 2H), 6.84– 6.76 (m, 2H), 4.99 (dd, *J* = 14.5 and 8.8 Hz, 1H), 4.84 (dd, *J* = 14.8 and 8.1 Hz, 1H), 4.62 (dd, *J* = 14.8 and 5.7 Hz, 1H), 4.52 (dd, *J* = 14.5 and 4.8 Hz, 1H), 4.26–4.18 (m, 4H), 4.12–4.04 (m, 1H), 4.00–3.89 (m, 3H), 1.31–1.14 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 13.9, 43.2, 43.3, 44.7, 44.8, 62.3, 62.4, 72.17, 72.23, 111.4, 111.5, 115.5, 127.2, 127.3, 127.6, 127.7, 132.0, 132.2, 140.2, 140.4, 168.9, 169.2, 175.2, 175.7; HPLC-MS (ESI) *t*_r = 7.7 min; [M + H]⁺ = 357.1, 359.1 *m*/*z*, [M + Na]⁺ = 379.1, 381.0 *m*/*z*. Anal. Calcd for C₁₃H₁₃BrN₂O₅ (356.00): C, 43.72; H

3.67; N, 7.84. Found: C, 43.69; H, 3.68; N, 7.83. CSP-HPLC: IC 90/10 *n*-Hex/IPA for 10 min, then up to 80/20 in 10 min, 80/20 for 15 min, then up to 75/25 in 15 min, 75/25 up to 40 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 27.7 min (major), 31.3 min (minor); t_r (isomer B) = 32.4 min (major), 33.0 min (minor).

tert-Butyl 6-chloro-3-((\hat{R})-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline-1-carboxylate (**3f**): mixture of two diastereoisomers; 92% yield (38 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.98–7.92 (m, 2H), 7.22–7.12 (m, 4H), 5.00 (dd, J = 14.3 and 9.0 Hz, 1H), 4.87 (dd, J = 14.8 and 7.5 Hz, 1H), 4.74 (dd, J = 14.8 and 6.4 Hz, 1H), 4.44 (dd, J = 14.4 and 5.3 Hz, 1H), 4.21–4.04 (m, 6H), 3.98 (d, J = 3.9 Hz, 1H), 3.92 (d, J = 2.7 Hz, 1H), 1.65 (s, 18H), 1.22–1.11 (m, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 13.7, 13.8, 28.0, 43.8, 44.0, 44.6, 45.0, 62.3, 62.4, 72.3, 72.5, 85.4, 85.5, 116.16, 116.23, 121.7, 122.3, 124.3, 124.5, 124.7, 124.8, 135.1, 135.4, 141.3, 141.5, 148.5, 168.4, 168.8, 172.2, 173.0; HPLC-MS (ESI) t_r = 10.9 min; [M + Na]⁺ = 435.2 m/z, [2M+Na]⁺ = 847.4 m/z. Anal. Calcd for C₁₈H₂₁ClN₂O₇ (412.10): C, 52.37; H, 5.13; N, 6.79. Found: C, 52.16; H, 5.13; N, 6.78.

6-Chloro-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, $CDCl_{2}$) δ 8.33 (bs, 2H), 7.19–7.02 (m, 4H), 6.95 (s, 2H), 4.99 (dd, J =14.4 and 9.0 Hz, 1H), 4.81 (dd, J = 14.7 and 8.3 Hz, 1H), 4.57 (dd, J = 14.7 and 5.5 Hz, 1H), 4.49 (dd, J = 14.4 and 5.1 Hz, 1H), 4.26–4.11 (m, 4H), 4.08 (ddd, J = 8.6 and 5.5 and 3.4 Hz, 1H), 4.01 (m, 1H), 3.93-3.87 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.2 Hz, 3H); ¹³C NMR $(50 \text{ MHz}, \text{CDCl}_3) \delta 13.8, 13.9, 43.1, 43.3, 44.5, 44.6, 62.26, 62.34, 72.1,$ 72.3, 110.9, 122.9, 123.0, 123.37, 123.42, 125.28, 125.32, 135.0, 135.2, 142.4, 168.9, 169.5, 176.4, 176.7; HPLC-MS (ESI) t_r = 7.3 min, 7.7 min; $[M + Na]^+ = 335.1 \ m/z$. Anal. Calcd for $C_{13}H_{13}ClN_2O_5$ (312.05): C, 49.93; H, 4.19; N, 8.96. Found: C, 49.77; H, 4.18; N, 8.93. CSP-HPLC: IC 90/10 n-Hex/IPA for 35 min, then up to 80/20 in 15 min, 80/20 for 10 min, then up to 70/30 in 5 min, 70/30 for 5 min, then up to 1/1 in 2 min, 1/1up to 73 min; flow rate 0.6 mL/min at room temperature; λ 254 nm; t_r (isomer A) = 33.4 min (major), 52.7 min (minor); t_r (isomer B) = 44.1 min (minor), 68.4 min (major).

tert-Butyl 7-bromo-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2oxoindoline-1-carboxylate (**3g**): mixture of two diastereoisomers; 82% yield (37 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.56–7.47 (m, 2H), 7.22–7.16 (m, 2H), 7.05 (t, *J* = 7.8 Hz, 2H), 5.01 (dd, *J* = 14.4 and 9.0 Hz, 1H), 4.88 (dd, *J* = 14.9 and 7.5 Hz, 1H), 4.74 (dd, *J* = 14.9 and 6.4 Hz, 1H), 4.44 (dd, *J* = 14.4 and 5.1 Hz, 1H), 4.20–4.05 (m, 6H), 4.04 (d, *J* = 3.9 Hz, 1H), 3.99 (d, *J* = 3.2 Hz, 1H), 1.66 (s, 9H), 1.65 (s, 9H), 1.15 (t, *J* = 7.6 Hz, 3H), 1.12 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 13.6, 13.7, 27.7, 43.7, 44.0, 45.2, 45.6, 62.5, 72.3, 72.4, 86.0, 86.1, 106.5, 106.6, 122.6, 122.8, 125.49, 125.54, 127.0, 127.6, 134.0, 134.3, 139.3, 139.5, 147.5, 168.4, 168.6, 173.0, 173.7; HPLC-MS (ESI) *t*_r = 10.5 min; [M + Na]⁺ = 479.1, 481.2 *m*/*z*. Anal. Calcd for C₁₈H₂₁BrN₂O₇ (456.05): C, 47.28; H, 4.63; N, 6.13. Found: C, 47.13; H, 4.64; N, 6.14.

7-Bromo-3-((R)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, $CDCl_3$) δ 8.07 (bs, 2H), 7.43 (d, J = 3.7 Hz, 1H), 7.41 (d, J = 3.7 Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 7.00–6.93 (m, 2H), 5.01 (dd, J = 14.4 and 9.0 Hz, 1H), 4.81 (dd, J = 14.8 and 8.4 Hz, 1H), 4.60 (dd, J = 14.8 and 5.5 Hz, 1H), 4.49 (dd, J = 14.5 and 4.6 Hz, 1H), 4.26–3.99 (m, 8H), 1.21 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 13.7, 13.8, 43.2, 43.3, 46.0, 46.2, 62.2, 62.3, 72.1, 72.4, 103.2, 103.3, 123.1, 124.1, 126.30, 126.34, 131.8, 132.0, 140.8, 141.04, 168.8, 169.3, 174.8, 175.2; HPLC-MS (ESI) $t_{\rm r}$ = 7.3 min, 7.6 min; $[M + H]^+ = 357.2$, 359.1 m/z, $[M + Na]^+ = 379.1$, 381.0 m/z. Anal. Calcd for C13H13BrN2O5 (356.00): C, 43.72; H, 3.67; N, 7.84. Found: C, 43.71; H, 3.68; N, 7.81. CSP-HPLC: IC 85:15 n-Hex/IPA for 15 min, then up to 80/20 in 10 min, 80/20 for 10 min, then up to 70/30 in 10 min, 70/30 up to 70 min; flow rate 0.5 mL/min at 14 $^{\circ}$ C; λ 214 nm; t_r (isomer A) = 48.4 min (major), 50.7 min (minor); t_r (isomer B) = 57.4 min (major), 66.1 min (minor).

tert-Butyl 3-((*R*)-1-ethoxy-3-nitro-1-oxopropan-2-yl)-5-methoxy-2-oxoindoline-1-carboxylate (**3***h*): mixture of two diastereoisomers; 89% yield (36 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 2.9 Hz, 1H), 7.77 (d, *J* = 2.9 Hz, 1H), 6.90–6.84 (m, 2H), 6.80 (dd, *J* = 2.6 and 1.1 Hz, 1H), 6.77 (dd, *J* = 2.6 and 1.2 Hz, 1H), 4.97 (dd, *J* = 14.5 and

9.1 Hz, 1H), 4.84 (dd, *J* = 14.8 and 8.1 Hz, 1H), 4.64 (dd, *J* = 14.8 and 5.8 Hz, 1H), 4.35 (dd, *J* = 14.5 and 4.6 Hz, 1H), 4.25–4.01 (m, 7H), 3.96 (d, *J* = 2.8 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 1.64 (s, 18H), 1.22–1.13 (m, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 13.7, 13.8, 28.1, 43.7, 43.9, 45.3, 45.7, 55.6, 55.7, 62.2, 62.3, 72.1, 72.5, 84.66, 84.74, 110.0, 110.2, 113.8, 113.9, 116.3, 116.4, 124.5, 125.0, 133.6, 133.8, 148.8, 156.97, 157.01, 168.7, 169.1, 172.6, 173.4; HPLC-MS (ESI) t_r = 9.9 min, 10.2 min; [M + Na]⁺ = 431.3 m/z, [2M + Na]⁺ = 839.6 m/z. Anal. Calcd for C₁₉H₂₄N₂O₈ (408.15): C, 55.88; H, 5.92; N, 6.86. Found: C, 55.77; H, 5.93; N, 6.87.

3-((R)-1-Ethoxy-3-nitro-1-oxopropan-2-yl)-5-methoxy-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, $CDCl_3$) δ 8.45 (bs, 2H), 6.90–6.73 (m, 6H), 4.96 (dd, J = 14.5 and 9.3 Hz, 1H), 4.76 (dd, J = 14.8 and 8.9 Hz, 1H), 4.49-4.35 (m, 2H), 4.29-4.15 (m, 4H), 4.10 (ddd, J = 8.6, 4.8, and 3.3 Hz, 1H), 4.04-3.92 (m, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H); 13 C NMR (50 MHz, CDCl₃) δ 13.8, 13.9, 43.0, 43.3, 45.5, 45.6, 55.78, 55.84, 62.1, 62.2, 72.0, 72.1, 110.8, 111.6, 111.7, 113.7, 113.8, 126.1, 126.4, 134.6, 134.8, 156.09, 156.14, 169.1, 169.8, 176.5, 176.8; HPLC-MS (ESI) $t_r = 5.9 \text{ min}, 6.2 \text{ min}; [M + H]^+ = 309.2 m/z, [M + H]^+$ Na]⁺= 331.2, $[2M + Na]^+$ = 639.3 *m/z*. Anal. Calcd for C₁₄H₁₆N₂O₆ (308.10): C, 54.54; H, 5.23; N, 9.09. Found: C, 54.42; H, 5.24; N, 9.12. CSP-HPLC: OD-H 85:15 n-Hex/IPA for 15 min, then up to 80/20 in 10 min, 80/20 for 10 min, then up to 70/30 in 10 min, 70/30 up to 41 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 24.9 min (major), 33.4 min (minor); t_r (isomer B) = 31.3 min (minor), 36.3 min (major).

tert-Butyl³ 3-((R)-1-(benzyloxy)-3-nitro-1-oxopropan-2-yl)-2-oxoindoline-1-carboxylate (**3i**): mixture of two diastereoisomers; 72% yield (32 mg), oil; ¹H NMR (200 MHz, CDCl₃) δ 7.80 (d, *J* = 8.2 Hz, 2H), 7.41–6.95 (m, 16H), 5.15 (s, 2H), 5.10 (s, 2H), 5.02 (dd, *J* = 14.4 and 9.3 Hz, 1H), 4.81 (dd, *J* = 14.8 and 8.3 Hz, 1H), 4.58 (dd, *J* = 14.9 and 5.5 Hz, 1H), 4.39 (dd, *J* = 14.5 and 4.6 Hz, 1H), 4.27–3.93 (m, 4H), 1.64 (s, 9H), 1.63 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) δ 28.0, 43.6, 43.7, 45.0, 45.4, 67.97, 68.02, 72.2, 84.9, 115.4, 115.5, 123.1, 123.3, 123.5, 124.6, 124.7, 128.4, 128.5, 128.6, 128.7, 129.2, 129.4, 134.4, 134.5, 140.2, 140.5, 148.6, 168.7, 169.1, 172.5, 173.2; HPLC-MS (ESI) *t*_r = 11.0 min, 11.2 min; [M + Na]⁺ = 463.3 *m/z*, [2M + Na]⁺ = 903.5 *m/z*. Anal. Calcd for C₂₃H₂₄N₂O₇ (440.16): C, 62.72; H, 5.49; N, 6.36. Found: C, 62.71; H, 5.48; N, 6.35.

3-((R)-1-(Benzyloxy)-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, CDCl₃) δ 8.42 (bs, 2H), 7.39–7.30 (m, 6H), 7.30–7.20 (m, 7H), 7.18 (d, J = 7.5 Hz, 1H), 7.08–6.91 (m, 3H), 6.85 (t, J = 8.4 Hz, 1H), 5.26–5.08 (m, 4H), 5.01 (dd, J = 14.6 and 9.5 Hz, 1H), 4.76 (dd, J = 14.8 and 9.0 Hz, 1H), 4.51–4.38 (m, 2H), 4.16 (m, 1H), 4.10 (m, 1H), 3.98–3.91 (m, 2H); $^{13}\mathrm{C}$ NMR (50 MHz, CDCl_3) δ 43.0, 43.3, 44.98, 45.03, 67.8, 67.9, 71.9, 72.3, 110.3, 110.4, 122.96, 122.99, 124.3, 124.4, 124.6, 124.8, 128.4, 128.51, 128.54, 128.6, 128.7, 129.1, 129.3, 134.6, 134.7, 141.2, 141.5, 169.1, 169.7, 176.3, 176.5; HPLC-MS (ESI) $t_r = 8.4 \text{ min}$, 8.7 min; $[M + H]^+ = 341.1 \ m/z, \ [M + Na]^+ = 363.2 \ m/z.$ Anal. Calcd for C₁₈H₁₆N₂O₅ (340.11): C, 63.52; H, 4.74; N, 8.23. Found: C, 63.42; H, 4.73; N, 8.22. CSP-HPLC: OJ 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 20 min, 80/20 up to 105 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 77.1 min (minor), 90.9 min $(major); t_r(isomer B) = 84.8 min (major), 100.9 min (minor).$

tert-Butyl 3-((*R*)-1-(tert-butoxy)-3-nitro-1-oxopropan-2-yl)-2-oxoindoline-1-carboxylate (**3***j*): mixture of two diastereoisomers; 99% yield (40 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.1 Hz, 1H), 7.86 (d, *J* = 8.1 Hz, 1H), 7.40–7.32 (m, 2H), 7.28–7.14 (m, 4H), 5.06 (dd, *J* = 14.2 and 9.0 Hz, 1H), 4.88 (dd, *J* = 14.7 and 8.1 Hz, 1H), 4.69 (dd, *J* = 14.7 and 6.0 Hz, 1H), 4.49 (dd, *J* = 14.1 and 5.6 Hz, 1H), 4.15 (ddd, *J* = 8.9 and 5.7 and 2.9 Hz, 1H), 4.00 (ddd, *J* = 8.1 and 6.0 and 3.3 Hz, 1H), 3.93 (d, *J* = 3.2 Hz, 1H), 3.82 (d, *J* = 2.8 Hz, 1H), 1.65 (s, 9H), 1.64 (s, 9H), 1.30 (s, 9H), 1.19 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) δ 27.3, 27.5, 28.1, 44.5, 44.9, 45.1, 45.5, 72.9, 73.3, 83.5, 84.8, 115.2, 115.3, 123.5, 123.6, 123.7, 124.3, 124.6, 129.0, 129.3, 140.3, 140.7, 148.9, 167.4, 167.9, 172.8, 173.4; HPLC-MS (ESI) *t*_r = 10.8 min, 11.1 min; [M + Na]⁺ = 429.4 *m/z*, [2M + Na]⁺ = 835.5 *m/z*. Anal. Calcd

for C₂₀H₂₆N₂O₇ (406.17): C, 59.10; H, 6.45; N, 6.89. Found: C, 58.95; H, 6.44; N, 6.91.

3-((*R*)-1-(tert-Butoxy)-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, syrup; ¹H NMR (400 MHz, CDCl₃) δ 8.06 (bs, 2H), 7.32–7.25 (m, 2H), 7.25–7.19 (m, 2H), 7.11–7.03 (m, 2H), 6.95–6.88 (m, 2H), 5.00 (dd, *J* = 14.2 and 9.3 Hz, 1H), 4.80 (dd, *J* = 14.7 and 9.1 Hz, 1H), 4.46 (ddd, *J* = 14.2 and 12.1 and 5.0 Hz, 2H), 4.08–3.96 (m, 2H), 3.91 (d, *J* = 3.5 Hz, 1H), 3.81 (d, *J* = 3.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 43.9, 44.0, 45.00, 45.2, 72.3, 73.1, 109.9, 110.0, 122.9, 122.8, 124.4, 124.5, 125.2, 125.4, 129.0, 129.2, 141.1, 141.6, 167.8, 168.7, 176.2, 176.3; HPLC-MS (ESI) *t*_r = 7.3 min, 7.9 min; [M + H]⁺ = 251.1 *m*/*z*. Anal. Calcd for C₁₁H₁₀N₂O₅ (250.06): C, 52.80; H, 4.03; N, 11.20. Found: C, 52.74; H, 4.01; N, 11.23. CSP-HPLC: OJ 90/ 10 *n*-Hex/IPA for 10 min, then up to 80/20 in 20 min, 80/20 up to 56 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; *t*_r(isomer A) = 27.6 min (major), 38.4 min (minor); *t*_r(isomer B) = 33.0 min (major), 52.2 min (minor).

tert-Butyl 3-((S)-2-nitro-1-phenylethyl)-2-oxoindoline-1-carboxylate (**3k**): mixture of two diastereoisomers; 52% yield (20 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.2 Hz, 1H), 7.57 (d, *J* = 8.0 Hz, 1H), 7.35–7.08 (m, 10H), 7.08–6.95 (m, 5H), 6.63 (d, *J* = 7.5 Hz, 1H), 5.43–5.29 (m, 2H), 5.12 (dd, *J* = 13.9 and 7.9 Hz, 1H), 4.92 (dd, *J* = 13.1 and 9.0 Hz, 1H), 4.25 (td, *J* = 7.6 and 3.8 Hz, 1H), 4.03 (m, 1H), 3.92 (d, *J* = 3.7 Hz, 1H), 3.80 (d, *J* = 7.8 Hz, 1H), 1.65 (s, 18H); ¹³C NMR (100 MHz, CDCl₃) δ 27.99, 28.01, 45.5, 46.0, 48.2, 48.7, 75.7, 77.1, 84.5, 84.6, 114.9, 115.0, 123.9, 124.1, 124.3, 124.4, 124.6, 124.8, 128.0, 128.2, 128.4, 128.48, 128.53, 128.7, 128.8, 129.0, 134.1, 135.2, 140.2, 140.4, 148.5, 148.6, 173.5, 173.9; HPLC-MS (ESI) *t*_r = 10.6 min; [M + Na]⁺ = 405.2 *m*/*z*. Anal. Calcd for C₂₁H₂₂N₂O₅ (382.15): C, 65.96; H, 5.80; N, 7.33. Found: C, 65.87; H, 5.81; N, 7.32.

3-((S)-2-Nitro-1-phenylethyl)-2-oxoindoline: mixture of two diastereoisomers, amorphous solid; ¹H NMR (400 MHz, $CDCl_3$) δ 7.33– 7.00 (m, 14H), 6.93-6.85 (m, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.67 (d, J =7.7 Hz, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.48 (dd, J = 13.1 and 6.7 Hz, 1H), 5.35 (dd, J = 13.7 and 7.3 Hz, 1H), 5.14 (dd, J = 13.7 and 8.0 Hz, 1H), 4.92 (dd, J = 13.1 and 9.1 Hz, 1H), 4.29 (dt, J = 7.7 and 4.0 Hz, 1H), 4.01 (m, 1H), 3.84 (d, J = 3.9 Hz, 1H), 3.73 (d, J = 8.3 Hz, 1H); 13 C NMR (50 MHz, CDCl₃) δ 44.5, 45.3, 47.9, 48.6, 75.8, 77.5, 109.8, 110.0, 122.4, 122.5, 124.4, 125.4, 126.26, 126.32, 128.0, 128.1, 128.40, 128.45, 128.50, 128.53, 128.8, 134.9, 136.0, 141.2, 141.5, 177.4, 177.5; HPLC-MS (ESI) $t_r = 7.6 \text{ min}; [M + H]^+ = 283.3 m/z, [M + Na]^+ = 305.3 m/z.$ Anal. Calcd for C₁₆H₁₄N₂O₃ (282.10): C, 68.07; H, 5.00; N, 9.92. Found: C, 67.94; H, 5.00; N, 9.96. CSP-HPLC: IC 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 5 min, 80/20 for 15 min, then up to 70/30 in 5 min, 70/30 up to 36 min; flow rate 0.5 mL/min at room temperature; λ 230 nm; t_r (isomer A) = 25.0 min (minor), 26.8 min (major); t_r (isomer B) = 29.7 min (major), 31.7 min (minor).

tert-Butyl 3-((S)-2-nitro-1-(4-nitrophenyl)ethyl)-2-oxoindoline-1carboxylate (**3**): mixture of two diastereoisomers; 98% yield (42 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.5 Hz, 2H), 8.00 (d, *J* = 8.8 Hz, 2H), 7.73 (d, *J* = 8.2 Hz, 1H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.40–7.30 (m, 2H), 7.30–7.17 (m, 6H), 7.16–7.07 (m, 1H), 6.85 (d, *J* = 7.6 Hz, 1H), 5.42–5.22 (m, 3H), 4.97 (dd, *J* = 13.4 and 9.5 Hz, 1H), 4.37 (ddd, *J* = 8.5 and 6.8 and 3.9 Hz, 1H), 4.32–4.23 (m, 1H), 3.98 (d, *J* = 3.8 Hz, 1H), 3.88 (d, *J* = 6.7 Hz, 1H), 1.58 (s, 18H); ¹³C NMR (50 MHz, CDCl₃) δ 27.97, 28.00, 45.1, 45.5, 48.1, 48.5, 75.4, 85.1, 115.2, 115.4, 123.3, 123.6, 123.7, 123.8, 124.4, 124.5, 124.7, 129.2, 129.3, 129.5, 129.6, 140.0, 140.5, 141.5, 142.4, 147.7, 147.9, 148.2, 148.3, 172.8, 173.4; HPLC-MS (ESI) *t*_r = 10.7 min; [M + Na]⁺ = 450.2 *m/z*, [2M + Na]⁺ = 877.7 *m/z*. Anal. Calcd for C₂₁H₂₁N₃O₇ (427.14): C, 59.01; H, 4.95; N, 9.83. Found: C, 58.85; H, 4.94; N, 9.81.

3-((S)-2-Nitro-1-(4-nitrophenyl)ethyl)-2-oxoindoline: mixture of two diastereoisomers, amorphous solid; ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.9 Hz, 2H), 8.01 (d, *J* = 8.8 Hz, 2H), 7.91 (bs, 1H), 7.38–7.23 (m, 6H), 7.19 (t, *J* = 7.2 Hz, 1H), 7.09 (t, *J* = 7.6 Hz, 1H), 7.01 (t, *J* = 7.6 Hz, 1H), 6.87–6.80 (m, 2H), 6.70 (d, *J* = 7.8 Hz, 1H), 5.41–5.26 (m, 3H), 4.97 (dd, *J* = 13.3 and 9.4 Hz, 1H), 4.41 (ddd, *J* = 8.3 and 6.9 and 4.0 Hz, 1H), 4.27 (dt, *J* = 9.4 and 6.7 Hz, 1H), 3.90 (d, *J* = 3.9 Hz, 1H), 3.81 (d, *J* = 6.9 Hz, 1H); ¹³C NMR (50 MHz, CDCl₃) δ 44.3, 44.9, 47.8, 48.3, 75.4, 76.6, 110.2, 110.4, 122.9, 123.0, 123.6, 123.9, 124.3, 125.0,

125.4, 129.1, 129.2, 129.4, 129.5, 140.8, 141.3, 142.1, 142.9, 147.6, 147.9, 176.4, 176.7; HPLC-MS (ESI) $t_r = 7.5 \text{ min}$, 7.6 min; $[M + H]^+ = 328.3 m/z$, $[M + Na]^+ = 350.1 m/z$. Anal. Calcd for $C_{16}H_{13}N_3O_5$ (327.09): C, 58.72; H, 4.00; N, 12.84. Found: C, 58.52; H, 4.01; N, 12.85. CSP-HPLC: IC 85:15 *n*-Hex/IPA for 20 min, then up to 80/20 in 20 min, 80/20 up to 52 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 39.0 min (minor), 46.8 min (major); t_r (isomer B) = 43.0 min (major), 45.5 min (minor).

tert-Butyl 3-((S)-3,3-dimethyl-1-nitrobutan-2-yl)-2-oxoindoline-1carboxylate (**3m**): mixture of two diastereoisomers; 62% yield (22 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, *J* = 8.3 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.38–7.11 (m, 6H), 4.71–4.47 (m, 4H), 3.82 (s, 1H), 3.74 (s, 1H), 3.05 (ddd, *J* = 10.4 and 4.7 and 1.7 Hz, 1H), 2.86 (m, 1H), 1.65 (s, 18H), 1.13 (s, 18H); ¹³C NMR (50 MHz, CDCl₃) δ 28.1, 28.3, 28.6, 33.7, 34.1, 45.3, 45.4, 48.0, 49.7, 73.7, 74.1, 84.4, 84.5, 115.0, 115.6, 123.3, 124.0, 124.4, 124.5, 127.4, 128.4, 128.8, 139.8, 140.8, 149.0, 149.1, 174.0, 175.7; HPLC-MS (ESI) t_r = 10.8 min, 11.2 min; [M + Na]⁺ = 385.2 *m/z*, [2M + Na]⁺ = 747.7 *m/z*. Anal. Calcd for C₁₉H₂₆N₂O₅ (362.18): C, 62.97; H, 7.23; N, 7.73. Found: C, 62.95; H, 7.24; N, 7.74.

3-((S)-3,3-Dimethyl-1-nitrobutan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, amorphous solid; ¹H NMR (400 MHz, CDCl₃) δ 8.32 (bs, 1H), 8.22 (bs, 1H), 7.31-7.16 (m, 4H), 7.13-6.98 (m, 2H), 6.95–6.81 (m, 2H), 4.74–4.47 (m, 4H), 3.72 (s, 1H), 3.66 (s, 1H), 3.06 (ddd, J = 9.9 and 4.9 and 1.7 Hz, 1H), 2.90 (ddd, J = 8.6 and 5.1 and 1.8 Hz, 1H), 1.14 (s, 18H); ¹³C NMR (50 MHz, CDCl₃) δ 28.4, 28.5, 33.7, 34.1, 45.4, 47.1, 48.8, 74.2, 74.6, 109.8, 110.3, 122.3, 122.7, 123.9, 125.1, 126.1, 128.3, 128.6, 129.1, 140.8, 141.8, 177.6, 179.5; HPLC-MS (ESI) $t_r = 7.8 \text{ min}, 8.4 \text{ min}; [M + H]^+ = 263.1 m/z, [M + Na]^+ = 285.2 m/z,$ $[2M + H]^+ = 525.3 \ m/z$. Anal. Calcd for $C_{14}H_{18}N_2O_3$ (262.13): C, 64.10; H, 6.92; N, 10.68. Found: C, 63.88; H, 6.94; N, 10.70. CSP-HPLC: IC 90/10 n-Hex/IPA for 15 min, then up to 80/20 in 10 min, 80/20 for 10 min, then up to 70/30 in 5 min, 70/30 for 5 min, then up to 1/1 in 1 min, 1/1 up to 53 min; flow rate 0.5 mL/min at room temperature; λ 254 nm; t_r (isomer A) = 31.5 min (major), 39.2 min (minor); t_r (isomer B) = 45.9 min (major), 47.7 min (minor).

tert-Butyl 3-((R)-1-Ethoxy-2-methyl-3-nitro-1-oxopropan-2-yl)-2oxoindoline-1-carboxylate (**3n**): mixture of two diastereoisomers; 57% yield (22 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.92–7.78 (m, 2H), 7.59 (d, *J* = 7.6 Hz, 1H), 7.41–7.29 (m, 2H), 7.22–7.12 (m, 2H), 7.04 (d, *J* = 7.6 Hz, 1H), 5.38 (d, *J* = 13.2 Hz, 1H), 5.15 (d, *J* = 13.2 Hz, 2H), 4.97 (d, *J* = 12.4 Hz, 1H), 4.46–4.33 (m, 4H), 3.95 (s, 1H), 3.94 (s, 1H), 1.65 (s, 9H), 1.64 (s, 9H), 1.38 (t, *J* = 7.2 Hz, 3H), 1.35 (t, *J* = 6.8 Hz, 3H), 1.13 (s, 6H); ¹³C NMR (50 MHz, CDCl₃) (major isomer) δ 13.9, 14.6, 28.1, 49.1, 49.9, 62.2, 80.0, 85.1, 115.0, 122.6, 124.6, 125.1, 129.4, 140.8, 148.6, 171.6, 172.8; HPLC-MS (ESI) *t*_r = 10.8 min; [M + Na]⁺ = 415.4 *m/z*, [2M + Na]⁺ = 807.5 *m/z*. Anal. Calcd for C₁₉H₂₄N₂O₇ (392.16): C, 58.16; H, 6.16; N, 7.14. Found: C, 58.08; H, 6.18; N, 7.15.

3-((R)-1-Ethoxy-2-methyl-3-nitro-1-oxopropan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (bs, 1H), 7.57 (bs, 1H), 7.40–7.19 (m, 3H), 7.09–6.94 (m, 3H), 6.88 (d, J = 7.6 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 5.46 (d, J =13.2 Hz, 1H), 5.17 (d, J = 12.8 Hz, 1H), 5.15 (d, J = 13.2 Hz, 1H), 4.93 (d, J = 12.8 Hz, 1H), 4.48 - 4.34 (m, 4H), 3.85 (s, 2H), 1.41 (t, J = 7.2 Hz, 1.41 (t, J = 7.2 Hz)3H), 1.37 (t, J = 7.2 Hz, 3H), 1.13 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) (major isomer) δ 14.1, 14.3, 48.4, 49.5, 62.2, 79.8, 109.8, 122.9, 124.3, 125.2, 129.2, 141.4, 171.9, 175.7; HPLC-MS (ESI) $t_r = 6.7 \text{ min}$, 7.4 min; $[M + H]^+ = 293.3 m/z$, $[M + Na]^+ = 315.2 m/z$, $[2M + Na]^+ =$ 607.4 m/z. Anal. Calcd for C14H16N2O5 (292.11): C, 57.53; H, 5.52; N, 9.58. Found: C, 57.51; H, 5.54; N, 9.56. CSP-HPLC: IC 90/10 n-Hex/ IPA for 10 min, then up to 80/20 in 5 min, 80/20 for 15 min, then up to 70/30 in 15 min, 70/30 up to 47 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 23.2 min (major), 29.0 min (minor); t_r (isomer B) = 35.3 min (minor), 41.6 min (major).

tert-Butyl 3-((2*R*,3*S*)-1-*ethoxy*-3-*nitro*-1-*oxobutan*-2-*yl*)-2-*oxoindoline*-1-*carboxylate* (*anti*-4*b*): mixture of two diastereoisomers; 71% yield (28 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (t, *J* = 8.6 Hz, 2H), 7.39–7.29 (m, 4H), 7.17 (t, *J* = 7.7 Hz, 2H), 5.67 (dq, *J* = 9.9 and 6.8 Hz, 1H), 5.30 (dq, *J* = 9.2 and 6.3 Hz, 1H), 3.99–3.91 (m, 4H), 3.91–3.84 (m, 1H), 3.80 (dd, *J* = 9.3 and 4.1 Hz, 1H), 3.74 (d, *J* = 4.3 Hz, 1H), 3.62 (d, *J* = 4.0 Hz, 1H), 1.78 (d, *J* = 6.5 Hz, 3H), 1.64

(m, 21H), 0.99 (t, J = 7.2 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.5, 13.6, 18.1, 18.9, 28.0, 28.1, 44.1, 45.3, 50.6, 51.5, 61.8, 61.8, 79.5, 81.8, 84.5, 84.7, 115.1, 115.2, 123.4, 123.7, 124.0, 124.4, 124.5, 124.6, 129.1, 129.3, 140.4, 140.5, 148.9, 149.1, 167.9, 168.1, 172.8, 172.9; HPLC-MS (ESI) $t_r = 10.3$ min, 10.4 min; $[M + Na]^+ = 415.3 m/z$. Anal. Calcd for $C_{19}H_{24}N_2O_7$ (392.16): C, 58.16; H, 6.16; N, 7.14. Found: C, 57.98; H, 6.18; N, 7.14.

3-((2R,3S)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, amorphous solid; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (bs, 1H), 8.01 (bs, 1H), 7.34–7.19 (m, 4H), 7.12–7.01 (m, 2H), 6.94–6.83 (m, 2H), 5.62 (dq, J = 9.6 and 6.9 Hz, 1H), 5.36 (dq, *J* = 8.6 and 6.6 Hz, 1H), 4.08–3.96 (m, 4H), 3.90 (dd, *J* = 9.6 and 4.4 Hz, 1H), 3.77 (dd, J = 8.5 and 5.2 Hz, 1H), 3.70 (d, J = 4.4 Hz, 1H), 3.60 (d, J = 5.2 Hz, 1H), 1.77 (d, J = 6.6 Hz, 3H), 1.62 (d, J = 6.9 Hz, 3H),1.02, (t, J = 7.1 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 13.67, 13.72, 17.4, 18.7, 44.0, 44.8, 49.8, 50.4, 61.68, 61.73, 79.5, 81.6, 109.8, 109.9, 122.5, 122.8, 124.6, 125.2, 125.3, 125.4, 128.9, 129.0, 141.2, 141.4, 168.3, 168.7, 176.3; HPLC-MS (ESI) $t_r = 6.9 \text{ min}$, 7.0 min; $[M + H]^+ = 293.3$ m/z, $[M + Na]^+ = 315.2 m/z$, $[2M + Na]^+ = 607.4 m/z$. Anal. Calcd for C14H16N2O5 (292.11): C, 57.53; H, 5.52; N, 9.58. Found: C, 57.39; H, 5.51; N, 9.55. CSP-HPLC: IC 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 5 min, 80/20 for 20 min, then up to 75/25 in 15 min, 75/25 up to 53 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 24.4 min (major), 31.5 min (minor); t_r (isomer B) = 39.8 min (minor), 47.0 min (major).

tert-Butyl 3-((2R,3S)-1-ethoxy-3-nitro-1-oxopentan-2-yl)-2-oxoindoline-1-carboxylate (anti-4c): mixture of two diastereoisomers; 76% yield (31 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (t, *J* = 8.0 Hz, 2H), 7.40–7.22 (m, 4H), 7.20–7.12 (m, 2H), 5.62 (ddd, *J* = 10.8 and 7.3 and 5.8 Hz, 1H), 5.16 (ddd, *J* = 10.3 and 8.3 and 5.0 Hz, 1H), 3.92 (q, *J* = 7.1 Hz, 2H), 3.89–3.81 (m, 3H), 3.77 (dd, *J* = 10.3 and 3.0 Hz, 1H), 3.62 (d, *J* = 4.3 Hz, 1H), 3.54–3.47 (m, 1H), 2.19–2.05 (m, 2H), 2.00–1.89 (m, 2H), 1.65 (s, 18H), 1.08 (t, *J* = 7.3 Hz, 3H), 1.03 (t, *J* = 7.3 Hz, 3H), 0.92 (t, *J* = 7.3 Hz, 3H), 1.03 (t, *J* = 7.3 Hz, 3H), 0.95 (t, *J* = 7.3 Hz, 3H), 0.92 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 9.6, 10.5, 13.4, 13.5, 26.3, 26.6, 28.0, 28.1, 44.0, 45.6, 49.9, 50.8, 61.76, 61.78, 84.5, 84.6, 85.4, 88.9, 115.0, 115.1, 123.1, 123.6, 123.9, 124.4, 124.6, 124.7, 129.1, 129.2, 140.4, 140.5, 148.9, 149.1, 167.9, 168.1, 172.6, 172.9; HPLC-MS (ESI) *t*_r = 10.9 min, 11.0 min; [M + Na]⁺ = 429.2 *m*/*z*. Anal. Calcd for C₂₀H₂₆N₂O₇ (406.17): C, 59.10; H, 6.45; N, 6.89. Found: C, 59.04; H, 6.43; N, 6.92.

3-((2R,3S)-1-Ethoxy-3-nitro-1-oxopentan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, CDCl₃) δ 8.14 (bs, 2H), 7.39-7.17 (m, 4H), 7.14-6.98 (m, 2H), 6.95-6.81 (m, 2H), 5.60 (ddd, J = 10.6 and 8.4 and 4.7 Hz, 1H), 5.25-5.12 (m, 1H), 4.00-3.80 (m, 5H), 3.73 (dd, J = 9.9 and 3.7 Hz, 1H), 3.56 (d, J = 4.4 Hz, 1H), 3.45 (d, J = 3.7 Hz, 1H), 2.24–2.05 (m, 2H), 2.05–1.87 (m, 2H), 1.11–1.05 (m, 3H), 1.02 (t, J = 7.3 Hz, 3H), 0.99–0.91 (m, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 9.7, 10.5, 13.5, 13.6, 26.2, 26.3, 44.1, 45.4, 49.3, 49.7, 61.6, 61.7, 85.5, 88.9, 109.9, 110.0, 122.5, 122.7, 124.4, 124.9, 125.3, 125.4, 128.9, 129.0, 141.6, 141.7, 168.2, 168.7, 176.7, 177.0; HPLC-MS (ESI) $t_r = 7.8 \text{ min}, 7.9 \text{ min}; [M + H]^+ = 307.3 m/z, [M + H]^+$ $Na]^+ = 329.1 m/z$, $[2M + Na]^+ = 635.5 m/z$. Anal. Calcd for C15H18N2O5 (306.12): C, 58.82; H, 5.92; N, 9.15. Found: C, 58.65; H, 5.91; N, 9.17. CSP-HPLC: IC 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 5 min, 80/20 for 20 min, then up to 75/25 in 15 min, 75/25 up to 58 min; flow rate 0.5 mL/min at room temperature; λ 230 nm; t_r (isomer A) = 21.9 min (major), 27.9 min (minor); t_r (isomer B) = 32.6 min (minor), 51.0 min (major).

(2R,3S)-1-*Ethyl 6-methyl 2-(*1-(*tert-butoxycarbonyl*)-2-*oxoindolin*-3-*yl*)-3-*nitrohexanedioate (anti-***4***d*): mixture of two diastereoisomers; 83% yield (39 mg), oil; ¹H NMR (400 MHz, CDCl₃) δ 7.91–7.79 (m, 2H), 7.40–7.28 (m, 4H), 7.22–7.13 (m, 2H), 5.70–5.60 (m, 1H), 5.41–5.26 (m, 1H), 4.06–3.92 (m, 3H), 3.92–3.77 (m, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 3.65 (d, *J* = 4.0 Hz, 1H), 3.53 (d, *J* = 2.4 Hz, 1H), 2.60–2.19 (m, 8H), 1.65 (s, 18H), 0.98 (t, *J* = 7.2 Hz, 3H), 0.93 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.4, 13.5, 27.8, 27.9, 28.0, 28.1, 29.8, 30.3, 44.0, 45.4, 49.9, 50.7, 51.9, 61.9, 62.0, 83.5, 84.5, 84.7, 86.3, 115.1, 115.2, 123.6, 123.7, 124.4, 124.5, 124.6, 124.7, 129.1, 129.3, 140.4, 140.5, 148.9, 149.0, 167.7, 167.8, 171.8, 172.5, 172.8; HPLC-MS (ESI) $t_r = 11.2$ min; [M + Na]⁺ = 487.3 *m/z*. Anal. Calcd for

 $\rm C_{22}H_{28}N_2O_9$ (464.18): C, 56.86; H, 6.08; N, 6.03. Found: C, 56.69; H, 6.08; N, 6.05.

(2R,3S)-1-Ethyl 6-methyl 3-nitro-2-(2-oxoindolin-3-yl)hexanedioate: mixture of two diastereoisomers, gum; ¹H NMR (400 MHz, CDCl₃) δ 7.71–7.50 (bs, 2H), 7.34–7.20 (m, 4H), 7.05 (t, J = 8.0Hz, 2H), 6.90-6.81 (m, 2H), 5.68-5.59 (m, 1H), 5.41-5.29 (m, 1H), 4.05–3.92 (m, 4H), 3.86 (dd, J = 10.0 and 4.4 Hz, 1H), 3.74 (dd, J = 9.2 and 4.4 Hz, 1H), 3.72 (s, 3H), 3.69 (s, 3H), 3.59 (d, J = 4.4 Hz, 1H), 3.51 (d, J = 4.4 Hz, 1H), 2.54–2.39 (m, 6H), 2.28–2.20 (m, 2H), 1.03–0.94 (m, 6H); 13 C NMR (100 MHz, CDCl₃) δ 13.6, 13.7, 27.4, 27.7, 29.9, 30.4, 43.9, 44.9, 49.4, 49.7, 51.9, 61.8, 61.9, 83.5, 86.1, 109.6, 109.7, 122.6, 122.9, 124.5, 124.9, 125.2, 125.3, 129.0, 129.1, 141.2, 141.4, 168.0, 168.4, 171.9, 171.9, 175.7, 175.9; HPLC-MS (ESI) $t_r = 7.3$ min; $[M + H]^+ = 365.3 m/z, [M + Na]^+ = 387.2 m/z, [2M + Na]^+ = 751.5$ m/z. Anal. Calcd for C₁₇H₂₀N₂O₇ (364.13): C, 56.04; H, 5.53; N, 7.69. Found: C, 55.83; H, 5.53; N, 7.68. CSP-HPLC: IC 80/20 n-Hex/IPA for 10 min, then up to 75/25 in 5 min, 75/25 for 25 min, then up to 65/35 in 15 min, 65/35 up to 67 min; flow rate 0.5 mL/min at room temperature; λ 254 nm; t_r (isomer A) = 26.8 min (major), 33.3 min (minor); t_r (isomer B) = 34.5 min (minor), 63.1 min (major).

tert-Butyl 3-((2R,3S)-1-ethoxy-3-nitro-1-oxo-4-phenylbutan-2-yl)-2-oxoindoline-1-carboxylate (anti-4e): mixture of two diastereoisomers; 72% yield (34 mg), amorphous solid; $^1\!\mathrm{H}$ NMR (400 MHz, CDCl₃) δ 7.88–7.78 (m, 2H), 7.39–7.24 (m, 12H), 7.22–7.13 (m, 4H), 5.86 (ddd, J = 4.4 and 8.4 and 10.4 Hz, 1H), 5.46 (dt, J = 2.8 and 10.4 Hz, 1H), 3.98-3.84 (m, 6H), 3.67 (d, J = 4.0 Hz, 1H), 3.53 (d, J = 2.8 Hz, 1H), 3.45 (dd, J = 2.8 and 14.4 Hz, 1H), 3.32 (dd, J = 10.8and 14.4 Hz, 1H), 3.28-3.16 (m, 2H), 1.66 (s, 9H), 1.65 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H), 0.95 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.4, 13.5, 28.0, 28.1, 39.0, 39.1, 44.2, 45.6, 49.8, 50.7, 61.9, 62.0, 84.6, 84.7, 85.7, 89.2, 115.1, 115.2, 123.0, 123.7, 123.8, 124.4, 124.6, 124.7, 127.7, 127.8, 128.8, 128.8, 128.9, 128.9, 129.0, 129.1, 129.3, 134.1, 135.1, 140.4, 140.5, 148.9, 168.0, 168.0, 172.4, 172.9; HPLC-MS (ESI) $t_{r} = 12.1$ min. 12.4 min; $[M + Na]^+ = 491.3 m/z$, $[2M + Na]^+ = 959.6 m/z$. Anal. Calcd for C₂₅H₂₈N₂O₇ (468.19): C, 64.09; H, 6.02; N, 5.98. Found: C, 64.02; H, 6.00; N, 6.00.

3-((2R,3S)-1-Ethoxy-3-nitro-1-oxo-4-phenylbutan-2-yl)-2-oxoindoline: mixture of two diastereoisomers, amorphous solid; ¹H NMR (400 MHz, CDCl₃) δ 8.12–7.89 (bs, 2H), 7.40–7.21 (m, 13H), 7.17 (d, J = 7.6 Hz, 1H), 7.13–7.00 (m, 2H), 6.96–6.82 (m, 2H), 5.88–5.79 (m, 1H), 5.53 (dt, J = 2.8 and 10.0 Hz, 1H), 4.08–3.92 (m, 4H), 3.90 (dd, J =2.0 and 9.6 Hz, 1H), 3.82 (dd, J = 4.0 and 9.2 Hz, 1H), 3.63 (d, J = 4.0 Hz, 1H), 3.52 (d, J = 4.0 Hz, 1H), 3.43 (dd, J = 3.6 and 14.8 Hz, 1H), 3.35 (dd, J = 10.0 and 14.4 Hz, 1H), 3.27-3.10 (m, 2H), 1.06 (t, J = 7.6 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 13.7, 38.5, 39.0, 44.3, 45.3, 49.3, 49.7, 61.8, 61.9, 85.8, 89.1, 110.0, 110.2, 122.6, 122.9, 124.5, 124.7, 124.8, 125.3, 127.6, 127.7, 128.8, 128.8, 128.9, 128.9, 129.0, 129.1, 134.4, 135.3, 141.4, 141.6, 168.3, 168.6, 176.3, 176.6; HPLC-MS (ESI) $t_r = 9.1 \text{ min}$, 9.2 min; $[M + H]^+ = 369.4 \text{ m/z}$, $[M + Na]^+ = 391.2 m/z, [2M + Na]^+ = 759.5 m/z$. Anal. Calcd for C₂₀H₂₀N₂O₅ (368.14): C, 65.21; H, 5.47; N, 7.60. Found: C, 65.15; H, 5.48; N, 7.59. CSP-HPLC: IC 90/10 n-Hex/IPA for 15 min, then up to 80/20 in 10 min, 80/20 for 15 min, then up to 70/30 in 10 min, 70/30 for 5 min, then up to 1/1 in 5 min, 1/1 up to 76 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (isomer A) = 27.2 min (major), 45.7 min (minor); t_r (isomer B) = 39.8 min (minor), 70.0 min (major).

tert-Butyl 3-((2R,3S)-1-ethoxy-2-methyl-3-nitro-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (5): major diastereoisomer; 72% yield (29 mg), syrup; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 8.0 Hz, 1H), 7.35 (t, *J* = 8.0 Hz, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 7.0 (d, *J* = 6.8 Hz, 1H), 5.50 (q, *J* = 6.8 Hz, 1H), 4.41–4.30 (m, 2H), 4.23 (s, 1H), 1.96 (d, *J* = 7.2 Hz, 3H), 1.65 (s, 9H), 1.36 (t, *J* = 6.8 Hz, 3H), 1.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 15.8, 15.8, 28.1, 48.9, 51.4, 62.2, 85.1, 88.5, 115.0, 124.1, 124.7, 129.2, 129.7, 140.7, 148.7, 170.6, 172.7; HPLC-MS (ESI) t_r = 11.6 min; [M + Na]⁺ = 429.4 m/z; [α]_D²⁵ = 19° (*c* = 0.48, CH₂Cl₂). Anal. Calcd for C₂₀H₂₆N₂O₇ (406.17): C, 59.10; H, 6.45; N, 6.89. Found: C, 59.04; H, 6.45; N, 6.91.

3-((2R,3S)-1-Ethoxy-2-methyl-3-nitro-1-oxobutan-2-yl)-2-oxoindoline: major diastereoisomer, syrup; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (bs, 1H), 7.05–6.97 (m, 2H), 6.90–6.84 (m, 2H), 5.59 (q, J = 6.4 Hz, 1H), 4.40–4.31 (m, 2H), 4.12 (s, 1H), 1.95 (d, J = 6.4 Hz, 3H), 1.37 (t, J = 7.2 Hz, 3H), 1.08 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 15.7, 15.8, 48.6, 50.7, 62.0, 88.2, 109.7, 123.0, 124.8, 129.0, 129.1, 141.3, 175.6, 178.5; HPLC-MS (ESI) $t_r = 8.2$ min; $[M + H]^+ = 307.3 m/z$, $[M + Na]^+ = 329.1 m/z$; $[\alpha]_D^{25} = 13^\circ$ (c = 0.13, CH₂Cl₂). Anal. Calcd for C₁₅H₁₈N₂O₅ (306.12): C, 58.82; H, 5.92; N, 9.15. Found: C, 58.58; H, 5.92; N, 9.16. CSP-HPLC: IC 90/10 *n*-Hex/IPA for 10 min, then up to 80/20 in 5 min, 80/20 up to 25 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (major isomer) = 14.5 min (major), 17.8 min (minor).

Synthesis of (S)-tert-Butyl 3-((R)-2,5-Dioxo-1-phenylpyrrolidin-3-yl)-3-((2R,3S)-1-ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (6). (E)-tert-Butyl 3-(2-ethoxy-2-oxoethylidene)-2-oxoindoline-1-carboxylate (2c; 0.1 mmol, 31.7 mg) was added to a solution of VI (10 mol %) in DCM (0.15 mL), and then nitroethane 1b (0.5 mmol) was added at 0 °C. The mixture was stirred at the same temperature until complete conversion (about 4.5 h). The solvent and the excess of 1b were quickly removed under vacuum (without heating), DCM (0.3 mL) was added, and N-phenylmaleimide (0.2 mmol) was finally added at 0 °C. The conversion was monitored by TLC and ¹H NMR until full conversion (1.5 h). The crude reaction mixture was directly purified by flash chromatography on silica gel (cyclohexane/ ethyl acetate 9/1): 81% yield (46 mg), gum; ¹H NMR (400 MHz, $CDCl_3$) δ 7.88 (d, J = 8.4 Hz, 1H), 7.48–7.37 (m, 4H), 7.27–7.25 (m, 1H), 7.20–7.13 (m, 3H), 5.95–5.85 (m, 1H), 4.89 (d, J = 4.8 Hz, 1H), 3.87–3.81 (m, 3H), 2.92 (dd, J = 9.2 and 18.0 Hz, 1H), 2.11 (dd, *I* = 5.2 and 18.0 Hz, 1H), 1.69 (s, 9H), 1.64 (d, *J* = 7.2 Hz, 3H), 0.94 $(t, J = 7.6 \text{ Hz}, 3\text{H}); {}^{13}\text{C} \text{ NMR} (100 \text{ MHz}, \text{CDCl}_3) \delta 13.6, 18.6, 28.1, 30.7,$ 42.0, 52.0, 52.8, 61.6, 79.0, 85.4, 115.7, 123.8, 124.4, 125.1, 126.4, 129.0, 129.2, 130.7, 131.1, 140.7, 144.6, 148.4, 168.2, 173.1, 174.4, 174.7; HPLC-MS (ESI) $t_r = 10.9 \text{ min}; [M - Boc + H]^+ = 466.4 m/z, [M + H_2O]^+ =$ 583.4 m/z; $[\alpha]_D^{25} = 107^\circ$ (c = 0.71, CH₂Cl₂). Anal. Calcd for C₂₉H₃₁N₃O₉ (565.21): C, 61.59; H, 5.52; N, 7.43. Found: C, 61.49; H, 5.54; N, 7.40. The absolute configuration of the stereocenters generated in the addition of N-phenylmaleimide was not experimentally determined, but it was indicated on the basis of that obtained with the same catalyst promoting the same reaction on similar substrates.²⁰

Synthesis of (R)-tert-Butyl 3-(2,2-Bis(phenylsulfonyl)ethyl)-3-((2R,3S)-1-ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxoindoline-1carboxylate (7). (E)-tert-Butyl 3-(2-ethoxy-2-oxoethylidene)-2-oxoindoline-1-carboxylate (2c; 0.1 mmol, 31.7 mg) was added to a solution of VI (10 mol %) in DCM (0.15 mL), and then nitroethane 1b (0.5 mmol) was added at 0 °C. The mixture was stirred at the same temperature until complete conversion (about 4.5 h). The solvent and the excess of 1b were quickly removed under vacuum (without heating), toluene (0.6 mL) was added, and 1,1-bis(benzenesulfonyl)-ethylene (0.2 mmol) was finally added at -10 °C. The conversion was monitored by TLC and ¹H NMR until full conversion (overnight). The reaction mixture was quenched with 2 mL of HCl (1 N) at 0 °C and extracted with ethyl acetate $(3 \times 3 \text{ mL})$. The organic phases were collected and dried over Na₂SO₄. The solvent was evaporated under reduced pressure, and the product was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 8/2): 68% yield (48 mg), syrup; ¹H NMR (400 MHz, CDCl₃) δ 7.99–7.93 (m, 3H), 7.79 (d, J = 7.2 Hz, 2H), 7.73–7.66 (m, 2H), 7.61–7.50 (m, 5H), 7.44 (t, J = 7.6 Hz, 1H), 7.27–7.24 (m, 1H), 5.16–5.09 (m, 1H), 4.41 (dd, J = 3.2 and 6.0 Hz, 1H), 4.13 (d, J = 5.2 Hz, 1H, 4.01 (q, J = 7.2 Hz, 2H), 2.94 (dd, J = 5.6 and 16.0 Hz, 1H), 2.85 (dd, J = 2.8 and 16.0 Hz, 1H), 1.64 (s, 9H), 1.38 (d, J = 6.8 Hz, 3H), 1.07 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 17.4, 28.1, 29.6, 50.9, 55.9, 61.8, 79.2, 79.4, 84.8, 116.0, 124.7, 125.6, 126.2, 128.9, 129.0, 129.7, 130.1, 131.0, 134.5, 134.9, 135.6, 137.7, 140.7, 148.8, 168.0, 174.3; HPLC-MS (ESI) $t_r = 11.9 \text{ min}; [M-Boc+H]^+ = 601.3 m/z, [M + 10.0 \text{ m}]$ $H_2O]^+ = 718.4 \ m/z; \ [\alpha]_D^{25} = 8^\circ \ (c = 0.54, \ CH_2Cl_2).$ Anal. Calcd for C₃₃H₃₆N₂O₁₁S₂ (700.18): C, 56.56; H, 5.18; N, 4.00. Found: C, 56.38; H, 5.17; N, 4.01. The absolute configuration of the stereocenter generated in the addition of 1,1-bis(benzenesulfonyl)ethylene was not experimentally determined, but it was indicated on the basis of that obtained with the same catalyst promoting the same reaction on similar substrates.21b

Synthesis of (R)-tert-Butyl 3-((2R,3S)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-3-((S)-2-nitro-1-phenylethyl)-2-oxoindoline-1carboxylate (8). (E)-tert-Butyl 3-(2-ethoxy-2-oxoethylidene)-2-oxoindoline-1-carboxylate (2c; 0.1 mmol, 31.7 mg) was added to a solution of VI (10 mol %) in DCM (0.15 mL), and then nitroethane 1b (0.5 mmol) was added at 0 °C. The mixture was stirred at the same temperature until complete conversion (about 4.5 h). The solvent and the excess of 1b were quickly removed under vacuum (without heating), DCM (0.3 mL) was added, and *trans-\beta*-nitrostyrene (0.2 mmol) was finally added at -40 °C. The conversion was monitored by TLC and ¹H NMR (90% of conversion after 24 h). The reaction mixture was quenched with 2 mL of HCl (1 N) and extracted with ethyl acetate (3 \times 2 mL). The organic phases were collected and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the product was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 9/1): 76% yield (41 mg), syrup. Major diastereoisomer: ¹H NMR (400 MHz, $CDCl_3$) δ 7.88–7.82 (m, 1H), 7.65–7.41 (m, 3H), 7.23–7.15 (m, 2H), 7.10-6.97 (m, 2H), 6.86 (d, J = 7.6 Hz, 1H), 5.37-5.23 (m, 2H), 4.52-4.36 (m, 3H), 4.17 (dd, J = 3.2 and 10.4 Hz, 1H), 4.13 (d, J = 6.8 Hz, 1H), 1.64 (d, J = 7.2 Hz, 3H), 1.63 (s, 9H), 1.39 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 17.8, 28.0, 50.0, 51.9, 55.8, 62.9, 75.1, 81.6, 85.1, 114.8, 115.2, 123.7, 124.4, 124.6, 126.3, 127.9, 128.4, 129.1, 129.8, 132.8, 139.8, 147.8, 168.9, 174.2; HPLC-MS (ESI) $t_r = 12.1 \text{ min};$ $[M + Na]^+ = 564.3 \ m/z, [2M + Na]^+ = 1105.7 \ m/z; [\alpha]_D^{25} = 16^\circ (c = 10.5 \text{ m})$ 0.91, CH₂Cl₂). Anal. Calcd for C₂₇H₃₁N₃O₉ (541.21): C, 59.88; H, 5.77; N, 7.76. Found: C, 59.65; H, 5.77; N, 7.77. The absolute configuration of the stereocenters generated in the addition of $trans-\beta$ -nitrostyrene was not experimentally determined, but it was indicated on the basis of that obtained with the same catalyst promoting the same reaction on similar substrates.221

Synthesis of (S)-tert-Butyl 3-((2R,3S)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxo-3-((R)-3-oxocyclohexyl)indoline-1-carboxylate (9). (E)-tert-Butyl 3-(2-ethoxy-2-oxoethylidene)-2-oxoindoline-1carboxylate (2c; 0.1 mmol, 31.7 mg) was added to a solution of VI (10 mol %) in DCM (0.15 mL), and then nitroethane 1b (0.5 mmol) was added at 0 °C. The mixture was stirred at the same temperature until complete conversion (about 4.5 h). The reaction mixture was guenched with 2 mL of HCl (1 N) at 0 °C and extracted with DCM (3×2 mL). The organic phases were collected and dried over Na₂SO₄. The solvent was evaporated under reduced pressure (without heating), and the crude mixture was directly used in the next transformation. Catalyst X·3HCl (10 mol %), triethylamine (30 mol %), and benzoic acid (20 mol %) were dissolved in toluene (0.3 mL). After the mixture was stirred at room temperature for 10 min, 2-cyclohexen-1-one (0.12 mmol) was added followed by the addition of crude 4b dissolved in toluene (0.3 mL). The mixture was stirred at room temperature for 48 h. The crude reaction mixture was directly purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 85/15): 65% yield (32 mg), gum; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 6.4 Hz, 1H), 7.20 (t, J = 6.8 Hz, 1H), 5.46–5.39 (m, 1H), 4.16 (d, *J* = 5.2 Hz, 1H), 3.95–3.87 (m, 2H), 2.45-2.33 (m, 3H), 2.10-2.03 (m, 2H), 1.90-1.78 (m, 2H), 1.66 (s, 9H), 1.58–1.46 (m, 2H), 1.49 (d, J = 6.8 Hz, 3H), 1.03 (t, J = 7.2 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 13.6, 18.2, 24.0, 25.6, 28.1, 40.7, 42.3, 43.1, 52.7, 54.8, 61.7, 79.4, 85.0, 115.1, 124.4, 124.8, 126.1, 129.6, 140.7, 148.6, 168.2, 175.1, 208.7; HPLC-MS (ESI) $t_r = 10.7 \text{ min}; [M - 10.7 \text{ min}]$ Boc + H]⁺ = 389.3 m/z_1 [M + H₂O]⁺ = 506.5 m/z_1 [2M + Na]⁺ = 999.8 m/z; $[\alpha]_{D}^{25} = -13^{\circ}$ (c = 1.02, CH₂Cl₂). Anal. Calcd for C₂₅H₃₂N₂O₈ (488.22): C, 61.46; H, 6.60; N, 5.73. Found: C, 61.35; H, 6.59; N, 5.75. The absolute configuration of the stereocenters generated in the addition of 2-cyclohexen-1-one was not experimentally determined, but it was indicated on the basis of that obtained with the same catalyst promoting the same reaction on similar substrates.^{10p}

Synthesis of (*S*)-*tert*-Butyl 3-((2*R*,3*S*)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxo-3-((*R*)-4-oxobutan-2-yl)indoline-1-carboxylate (10). To a solution of catalyst XI (20 mol %) and crude product 4b (0.1 mmol, prepared as described for product 9) in DCM (1 mL) at -40 °C were added benzoic acid (20 mol %) and then crotonaldehyde (0.15 mmol). After it was stirred at the same temperature for 24 h, the reaction mixture was quenched with 2 mL of HCl (1 N) at 0 °C and

extracted with DCM $(3 \times 2 \text{ mL})$. The organic phases were collected and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the crude mixture was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 9/1): 71% yield (33 mg), gum; mixture of two diastereoisomers; ¹H NMR (400 MHz, CDCl₂) δ 9.62 (d, J = 2.0 Hz, 1H), 9.61 (d, J = 2.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.43–7.32 (m, 4H), 7.20 (t, J = 7.6 Hz, 2H), 5.50–5.43 (m, 1H), 5.30–5.23 (m, 2H)1H), 4.13 (d, J = 5.6 Hz, 1H), 4.12 (d, J = 5.6 Hz, 1H), 3.99-3.88 (m, 4H), 2.86–2.77 (m, 2H), 2.65 (d, J = 16.4 Hz, 1H), 2.53 (d, J = 17.6 Hz, 1H), 2.23 (ddd, J = 2.8, 10.8, and 14.0 Hz, 1H), 2.08 (ddd, J = 2.4 and 10.4 and 12.4 Hz, 1H), 1.66 (s, 18H), 1.53 (d, J = 6.8 Hz, 3H), 1.51 (d, *J* = 6.8 Hz, 3H), 1.06 (t, *J* = 7.2 Hz, 3H), 1.02 (t, *J* = 7.2 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 13.7, 15.0, 18.1, 28.1, 32.6, 33.2, 45.4, 45.7, 53.0, 53.0, 54.7, 61.7, 61.8, 79.3, 79.9, 84.8, 84.9, 115.0, 115.1, 124.3, 124.4, 124.5, 124.7, 126.3, 126.3, 129.5, 140.3, 140.6, 148.6, 148.7, 168.1, 168.3, 175.5, 175.7, 199.5, 200.0; HPLC-MS (ESI) $t_r = 10.7 \text{ min}; [M - Boc + H]^+ =$ 363.4 m/z, $[M + H_2O]^+ = 480.4 m/z$, $[M + Na]^+ = 485.3 m/z$, $[2M + Na]^+ = 485.3 m/z$, [2M +Na]⁺ = 947.8 m/z. Anal. Calcd for C₂₃H₃₀N₂O₈ (462.20): C, 59.73; H, 6.54; N, 6.06. Found: C, 59.68; H, 6.52; N, 6.08. The absolute configuration of the stereocenters generated in the addition of crotonaldehyde was not experimentally determined, but it was indicated on the basis of that obtained with the same catalyst promoting the same reaction on similar substrates.8

Synthesis of tert-Butyl 3-((2R,3S)-3-Amino-1-ethoxy-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (11a,b). Compound 4b (0.38 mmol, 149 mg) was dissolved in EtOH (5.5 mL), Raney nickel (6 drops of the commercially available suspension in water) was added, and the reaction mixture was stirred at room temperature under an H₂ balloon overnight. Then it was filtered and washed with ethyl acetate and DCM. The solvent was removed under reduced pressure, and the diastereomeric mixture of **11a** and **11b** (dr = 54/46) was obtained pure: 95% yield (131 mg), oil; mixture of two diastereoisomers; ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3) \delta 7.73 \text{ (bs, 2H)}, 7.31-7.22 \text{ (m, 4H)}, 7.18 \text{ (d, } J = 6.8 \text{ (d, } J = 6.$ Hz, 1H), 7.14–7.09 (m, 2H), 7.04 (t, J = 7.2 Hz, 1H), 6.43 (bs, 2H), 4.29 (d, J = 10.8 Hz, 2H), 4.24-4.16 (m, 2H), 3.98-3.84 (m, 2H), 3.28 (dd, J = 8.8 and 10.0 Hz, 1H), 3.09 (dd, J = 8.8 and 10.0 Hz, 1H), 1.53 (s, 9H), 1.52 (s, 9H), 1.44 (d, J = 6.0 Hz, 3H), 1.39 (d, J = 6.0 Hz, 3H), 1.25 $(t, J = 7.2 \text{ Hz}, 3\text{H}), 0.96 (t, J = 7.2 \text{ Hz}, 3\text{H}); {}^{13}\text{C} \text{NMR} (50 \text{ MHz}, \text{CDCl}_3)$ δ 13.6, 14.1, 21.3, 21.6, 28.4, 45.2, 47.4, 50.4, 51.0, 52.6, 54.4, 61.3, 61.8, 80.1, 80.3, 124.5, 124.7, 125.0, 126.7, 127.7, 128.1, 128.2, 137.1, 137.2, 151.0, 153.8, 169.5, 170.0, 171.8, 175.2; HPLC-MS (ESI) $t_r = 7.4 \text{ min}$, 8.0 min; $[M - Boc + H]^+ = 263.3 m/z$, $[M + H]^+ = 363.4 m/z$, $[2M + Na]^+ = 747.7 \ m/z$. Anal. Calcd for $C_{19}H_{26}N_2O_5$ (362.18): C, 62.97; H, 7.23; N, 7.73. Found: C, 62.84; H, 7.22; N, 7.72

Procedure for the Stereoconvergent Epimerization to (R)tert-Butyl 3-((2R,3S)-3-Amino-1-ethoxy-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (11a). The diastereomeric mixture of 11a and 11b (dr = 54/46; 0.1 mmol, 36.2 mg) was dissolved in acetone (0.6 mL), and K_2CO_3 (0.2 mmol) was added. The reaction mixture was stirred at 50 °C for 24 h, and the conversion was monitored by ¹H NMR. After completion, the solvent was removed, the residue was dissolved in water (3 mL), and this solution was extracted with DCM (3×3 mL). The organic phases were collected and dried over Na₂SO₄. The solvent was evaporated under reduced pressure, and compound 11a was obtained pure: 95% yield, 34 mg, oil; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (bs, 1H), 7.31–7.27 (m, 2H), 7.18 (d, J = 6.8 Hz, 1H), 7.12 (t, J = 7.2 Hz, 1H), 6.22 (bs, 1H), 4.28 (d, J = 10.4 Hz, 1H), 4.24–4.16 (m, 2H), 3.97-3.90 (m, 1H), 3.09 (dd, J = 10.8 and 8.0 Hz, 1H), 1.52 (s, 9H), 1.44 (d, J = 6.0 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 21.6, 28.4, 47.4, 51.0, 54.3, 61.8, 80.1, 124.6, 125.0, 127.6, 128.2, 128.4, 137.2, 153.7, 171.8, 175.2; HPLC-MS (ESI) $t_r = 8.0$ min; $[M - Boc + H]^+ = 263.1 m/z, [M + H]^+ = 363.2 m/z, [2M + Na]^+ = 747.2$ m/z; $[\alpha]_D^{25} = 34^\circ$ (c = 0.99, CH₂Cl₂). Anal. Calcd for C₁₉H₂₆N₂O₅ (362.18): C, 62.97; H, 7.23; N, 7.73. Found: C, 62.77; H, 7.24; N, 7.76.

Synthesis of 12a,b. Compound 4b (0.2 mmol, 78.5 mg) was dissolved in MeOH (3.5 mL), and Pd on C (20% w/w) was added. The reaction mixture was stirred at room temperature under an H₂ balloon overnight. Then it was filtered and washed with ethyl acetate and DCM. The solvent was evaporated under reduced pressure, and the crude

mixture was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 1/1): 90% yield, 68 mg, oil.

(*R*)-tert-Butyl 3-((2*R*,3*S*)-1-ethoxy-3-(hydroxyamino)-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (12a): ¹H NMR (400 MHz, CDCl₃) δ 7.64 (bs, 1H), 7.28–7.23 (m, 1H), 7.15–7.06 (m, 1H), 7.02–6.97 (m, 2H), 4.44–4.37 (m, 1H), 4.27 (d, *J* = 9.6 Hz, 1H), 3.94–3.76 (m, 2H), 3.20 (dd, *J* = 10.0 and 8.4 Hz, 1H), 1.54 (s, 9H), 1.44 (d, *J* = 5.6 Hz, 3H), 0.92 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 13.5, 18.3, 28.4, 42.2, 48.8, 55.7, 61.5, 80.5, 118.9, 125.0, 127.3, 128.5, 129.7, 136.9, 153.4, 168.3, 169.4; HPLC-MS (ESI) *t*_r = 7.0 min; [M – Boc + H]⁺ = 279.4 *m*/*z*, [2M + Na]⁺ = 779.6 *m*/*z*; [α]_D²⁵ = -5° (*c* = 0.67, CH₂Cl₂). Anal. Calcd for C₁₉H₂₆N₂O₆ (378.18): C, 60.30; H, 6.93; N, 7.40. Found: C, 60.28; H, 6.91; N, 7.39.

(*S*)-tert-Butyl 3-((2*R*,3*S*)-1-ethoxy-3-(hydroxyamino)-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (12*b*): ¹H NMR (400 MHz, CDCl₃) δ 7.74 (bs, 1H), 7.32–7.27 (m, 1H), 7.18–6.99 (m, 3H), 4.31–4.18 (m, 3H), 3.97–3.91 (m, 1H), 2.87 (t, *J* = 8.4 Hz, 1H), 1.53 (s, 9H), 1.47 (d, *J* = 5.6 Hz, 3H), 1.27 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 19.0, 28.4, 50.5, 51.3, 56.6, 62.1, 80.3, 118.6, 124.6, 128.2, 128.4, 129.7, 137.2, 153.7, 169.3, 171.4; HPLC-MS (ESI) *t*_r = 7.6 min; [M – Boc + H]⁺ = 279.2 *m*/*z*, [2M + Na]⁺ = 779.6 *m*/*z*; [α]_D²⁵ = 8° (*c* = 0.93, CH₂Cl₂). Anal. Calcd for C₁₉H₂₆N₂O₆ (378.18): C, 60.30; H, 6.93; N, 7.40. Found: C, 60.10; H, 6.94; N, 7.39.

Procedure for the Stereoconvergent Epimerization to 12a. A diastereomeric mixture of 12a and 12b (dr = 60/40; 0.1 mmol, 37.8 mg) was dissolved in EtOH (0.7 mL), and NaHCO₃ (10 drops of a saturated solution) was added. The reaction mixture was stirred at room temperature for 48 h, and the conversion was monitored by ¹H NMR. After completion, water (3 mL) was added to the mixture, and it was extracted with ethyl acetate (3 × 3 mL). The organic phases were collected and dried over Na₂SO₄. The solvent was evaporated under reduced pressure, and compound 12a was obtained pure (90% yield, 34 mg, oil).

Synthesis of ((2S,3R,3aR)-2,8-Dimethyl-2,3,3a,8tetrahydropyrrolo[2,3-b]indol-3-yl)methanol (13). anti-4b (0.2 mmol, 78.5 mg) was dissolved in EtOH (3 mL), Raney nickel (4 drops of the commercially available suspension in water) was added, and the reaction mixture was stirred at room temperature under an H₂ balloon overnight. Then the mixture was filtered and washed with ethyl acetate and DCM. The solvent was removed under reduced pressure, and the diastereomeric mixture of 11a and 11b (dr = 54/46) was obtained pure. The crude mixture was dissolved in acetone (1.5 mL), and K_2CO_3 (0.4 mmol) was added. The reaction mixture was stirred at 50 °C for 24 h, and the conversion was monitored by ¹H NMR. After completion, the solvent was removed, the residue was dissolved in water (5 mL), and this solution was extracted with DCM $(3 \times 6 \text{ mL})$. The organic phases were collected and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the crude product 11a was dissolved in THF (5 mL). LiAlH₄ (2 mmol) was added, and the mixture was heated at 75 °C for 2 h. It was cooled to room temperature and quenched with ethyl acetate (6 mL) and then H_2O (1.2 mL). The resulting mixture was filtered through Celite and washed with ethyl acetate and MeOH. The filtrates were concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (DCM/MeOH 20/1), providing compound 13: 72% yield over three steps, 31 mg, amorphous solid; ¹H NMR (400 MHz, CD₃OD) δ 7.14 (t, J = 8.0 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.70–6.66 (m, 2H), 3.72 (d, J = 8.0 Hz, 1H), 3.64 (dd, J = 12.0 and 4.0 Hz, 1H) 3.60 (dd, J = 12.0 and 4.0 Hz, 1H), 3.59-3.53 (m, 1H), 2.80 (s, 3H), 2.10–2.04 (m, 1H), 1.26 (d, J = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 21.8, 30.8, 47.2, 52.6, 54.6, 62.4, 111.7, 118.1, 125.3, 128.8, 129.2, 149.3, 179.7; HPLC-MS (ESI) $t_r = 2.2 \text{ min}; [M + H]^+ = 217.1$ m/z, $[M + H_2O + H]^+ = 235.3 m/z$, $[M + Na]^+ = 239.1 m/z$; $[\alpha]_D^{-25} = -14^\circ$ (c = 0.45, MeOH). Anal. Calcd for $C_{13}H_{16}N_2O(216.13)$: C, 72.19; H, 7.46; N, 12.95. Found: C, 72.16; H, 7.43; N, 12.99.

Synthesis of tert-Butyl 3-((2R,3R)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (syn-4b). anti-4b (0.1 mmol, 39 mg) was dissolved in DCM (0.4 mL), and DBU (1,5diazabiciclo[5.4.0] undec-5-ene, 30 mol %) was added. The reaction mixture was stirred at room temperature for 24 h, and the conversion was monitored by ¹H NMR. The solvent was evaporated under reduced

pressure, and the crude reaction mixture was directly purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 9/1): 70% yield, 27.5 mg, gum; mixture of two diastereoisomers (dr = 70/30); ¹H NMR (400 MHz, CDCl3) δ 7.89-7.82 (m, 2H), 7.38-7.27 (m, 3H), 7.21-7.12 (m, 3H), 5.33-5.23 (m, 2H), 4.13 (dd, J = 2.4 and 10.0 Hz, 1H), 4.05 (q, J = 6.8 Hz, 2H), 3.96-3.85 (m, 4H), 3.81 (s, 1H), 1.75 (d, I = 7.2 Hz, 3H), 1.67 - 1.64 (m, 21H), 1.08 (t, I = 7.2 Hz, 3H), 0.91 $(t, J = 7.2 \text{ Hz}, 3\text{H}); {}^{13}\text{C} \text{ NMR} (100 \text{ MHz}, \text{CDCl}_3) \delta 13.4, 13.6, 17.9, 18.4,$ 28.1, 44.4, 44.6, 49.1, 49.4, 61.8, 62.0, 80.9, 81.6, 84.8, 84.9, 115.3, 115.4, 123.5, 123.6, 123.7, 124.6, 124.6, 129.2, 129.4, 140.2, 140.5, 148.9, 168.6, 169.6, 173.0, 173.2; HPLC-MS (ESI) $t_r = 10.3 \text{ min}$, 10.4 min; $[M - Boc + H]^+ = 293.3 m/z, [M + H_2O]^+ = 410.3 m/z, [M + Na]^+ =$ 415.3 m/z. Anal. Calcd for C₁₉H₂₄N₂O₇ (392.16): C, 58.16; H, 6.16; N, 7.14. Found: C, 58.06; H, 6.18; N, 7.15. To check the optical purity of compound syn-4b, it was deprotected as previously described and injected in CSP-HPLC.

3-((2R,3R)-1-Ethoxy-3-nitro-1-oxobutan-2-yl)-2-oxoindoline: amorphous solid, mixture of two diastereoisomers (dr = 76/24), the signals of the major isomer have been described; ¹H NMR (400 MHz, $CDCl_3$) δ 7.82 (bs, 1H), 7.30–7.25 (m, 2H), 7.08 (t, J = 7.2 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 5.25-5.17 (m, 1H), 4.11 (q, J = 6.8 Hz, 2H), 3.91 (dd, J = 2.8 and 10.0 Hz, 1H), 3.87 (d, J = 2.8 Hz, 1H), 1.59 (d, J = 6.4 Hz, 3H), 1.13, (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 17.8, 44.3, 48.4, 61.9, 81.5, 110.0, 122.9, 124.7, 124.9, 129.1, 140.9, 170.3, 176.0; HPLC-MS (ESI) $t_r = 7.0 \text{ min}; [M + H]^+ = 293.3 m/z_r$ $[M + Na]^+ = 315.2 m/z, [2M + Na]^+ = 607.4 m/z$. Anal. Calcd for C14H16N2O5 (292.11): C, 57.53; H, 5.52; N, 9.58. Found: C, 57.35; H, 5.51; N, 9.62. CSP-HPLC: IC 90/10 n-Hex/IPA for 10 min, then up to 80/20 in 5 min, 80/20 for 20 min, then up to 75/25 in 15 min, 75/25 up to 47 min; flow rate 0.5 mL/min at room temperature; λ 214 nm; t_r (major isomer) = 25.4 min (minor), 34.0 min (major); t_r (minor isomer) = 28.6 min (major), 42.7 min (minor).

Synthesis of ((2R,3R,3aS)-2,8-Dimethyl-2,3,3a,8tetrahydropyrrolo[2,3-b]indol-3-yl)methanol (14). syn-4b (0.1 mmol, 39 mg) was dissolved in EtOH (2 mL), Raney nickel (3 drops of the commercially available suspension in water) was added, and the reaction mixture was stirred at room temperature under an H₂ balloon overnight. Then it was filtered and washed with ethyl acetate and DCM. The solvent was removed under reduced pressure, and the β -amino oxindole 15 was obtained pure as an oil. The crude 15 was dissolved in THF (3 mL), LiAlH₄ (1 mmol) was added, and the mixture was heated at 75 °C for 2 h. The mixture was cooled to room temperature and quenched with ethyl acetate (4 mL) and then H₂O (0.8 mL). The resulting mixture was filtered through Celite and washed with ethyl acetate and MeOH. The filtrates were concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (DCM/MeOH 20/1), providing compound 14: 76% yield over two steps, 16.5 mg, amorphous solid.

(S)-tert-Butyl 3-((2R,3R)-3-amino-1-ethoxy-1-oxobutan-2-yl)-2-oxoindoline-1-carboxylate (15): ¹H NMR (400 MHz, CDCl₃) δ 7.73 (bs, 1H), 7.32–7.23 (m, 2H), 7.15–7.08 (m, 2H), 5.88 (bs, 1H), 4.32 (d, *J* = 10.0 Hz, 1H), 4.28–4.13 (m, 3H), 3.64 (dd, *J* = 8.8 and 9.2 Hz, 1H), 1.54 (s, 9H), 1.30–1.26 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 18.0, 28.4, 43.5, 49.0, 51.7, 61.6, 80.0, 124.6, 127.6, 128.0, 128.1, 128.5, 137.4, 153.7, 171.2, 176.2; HPLC-MS (ESI) t_r = 7.7 min; [M – Boc + H]⁺ = 263.3 *m*/*z*, [M + H]⁺ = 363.4 *m*/*z*; [α]_D²⁵ = 19° (*c* = 1.69, CH₂Cl₂). Anal. Calcd for C₁₉H₂₆N₂O₅ (362.18): C, 62.97; H, 7.23; N, 7.73. Found: C, 62.77; H, 7.21; N, 7.72.

((2*R*,3*R*,3*a*S)-2,8-Dimethyl-2,3,3*a*,8-tetrahydropyrrolo[2,3-b]indol-3-yl)methanol (**14**): ¹H NMR (400 MHz, CD₃OD) δ 7.14 (t, *J* = 7.6 Hz, 1H), 6.97 (d, *J* = 7.2 Hz, 1H), 6.72-6.65 (m, 2H), 3.95-3.88 (m, 1H), 3.75 (dd, *J* = 7.6 and 10.8 Hz, 1H) 3.66 (d, *J* = 6.4 Hz, 1H), 3.56 (dd, *J* = 7.6 and 10.4 Hz, 1H), 2.81 (s, 3H), 2.54-2.47 (m, 1H), 1.22 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CD₃OD) δ 16.0, 30.8, 47.0, 51.3, 60.8, 111.6, 117.9, 124.0, 128.0, 129.2, 149.3, 180.1; HPLC-MS (ESI) $t_r = 2.1 \text{ min; } [M + H_2O + H]^+ = 235.3 m/z, [2M + Na]^+ = 455.5 m/z; [\alpha]_D^{25} = 15° (c = 0.15, MeOH). Anal. Calcd for C₁₃H₁₆N₂O (216.13): C, 72.19; H, 7.46; N, 12.95. Found: C, 72.16; H, 7.45; N, 13.00.$

ASSOCIATED CONTENT

S Supporting Information

Text, tables, and figures giving details of the determination of the relative and absolute configurations, ¹H and ¹³C NMR spectra of new compounds, and CSP-HPLC traces. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail for A.Q.: arianna.quintavalla@unibo.it.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support was provided by Miur-Rome (PRIN 20099PKPHH_004), Fondazione del Monte di Bologna e Ravenna, and COST Action CM0905 "Organocatalysis".

REFERENCES

For reviews on biologically active oxindole-containing compounds, see: (a) Millemaggi, A.; Taylor, R. J. K. *Eur. J. Org. Chem.* 2010, 4527.
 (b) Bhrigu, B.; Pathak, D.; Siddiqui, N.; Alam, M. S.; Ahsan, W. *Int. J. Pharm. Sci. Drug Res.* 2010, *2*, 229. (c) Raj, V. *Int. J. Curr. Pharm. Res.* 2012, *4*, 1.

(2) For recent examples of bioactive oxindole derivatives, see: (a) Fensome, A.; Adams, W. R.; Adams, A. L.; Berrodin, T. J.; Cohen, J.; Huselton, C.; Illenberger, A.; Kern, J. C.; Hudak, V. A.; Marella, M. A.; Melenski, E. G.; McComas, C. C.; Mugford, C. A.; Slayden, O. D.; Yudt, M.; Zhang, Z.; Zhang, P.; Zhu, Y.; Winneker, R. C.; Wrobel, J. E. J. Med. Chem. 2008, 51, 1861. (b) Canner, J.; Sobo, M.; Ball, S.; Hutzen, B.; DeAngelis, S.; Willis, W.; Studebaker, A. W.; Ding, K.; Wang, S.; Yang, D.; Lin, J. Br. J. Cancer 2009, 101, 774. (c) Franz, A. K.; Dreyfuss, P. D.; Schreiber, S. L. J. Am. Chem. Soc. 2007, 129, 1020. (d) Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3933. (e) Rottmann, M.; McNamara, C.; Yeung, B. K. S.; Lee, M. C. S.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; González-Páez, G. E.; Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H.-P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; Fidock, D. A.; Winzeler, E. A.; Diagana, T. T. Science 2010, 329, 1175.

(3) For examples of total synthesis, see: (a) Albrecht, B. K.; Williams, R. M. Org. Lett. 2003, 5, 197. (b) Lin, H.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003, 42, 36. (c) Greshock, T. J.; Grubbs, A. W.; Jiao, P.; Wicklow, D. T.; Gloer, J. B.; Williams, R. M. Angew. Chem., Int. Ed. 2008, 47, 3573. (d) Reisman, S. E.; Ready, J. M.; Weiss, M. M.; Hasuoka, A.; Hirata, M.; Tamaki, K.; Ovaska, T. V.; Smith, C. J.; Wood, J. L. J. Am. Chem. Soc. 2008, 130, 2087. For reviews on the synthetic approaches, see: (e) Galliford, C. V.; Scheidt, K. A. Angew. Chem., Int. Ed. 2007, 46, 8748. (f) Marti, C.; Carreira, E. M. Eur. J. Org. Chem. 2003, 2209. (g) Trost, B. M.; Brennan, M. K. Synthesis 2009, 18, 3003.

(4) (a) Ma, S.; Han, X.; Krishnan, S.; Virgil, S. C.; Stoltz, B. M. Angew. Chem., Int. Ed. 2009, 48, 8037. (b) Trost, B. M.; Zhang, Y. Chem. Eur. J. 2011, 17, 2916. (c) Trost, B. M.; Cramer, N.; Silverman, S. M. J. Am. Chem. Soc. 2007, 129, 12396. (d) Kato, Y.; Furutachi, M.; Chen, Z.; Mitsunuma, H.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2009, 131, 9168. (e) Antonchick, A. P.; Gerding-Reimers, C.; Catarinella, M.; Schürmann, M.; Preut, H.; Ziegler, S.; Rauh, D.; Waldmann, H. Nat. Chem. 2010, 2, 735.

(5) (a) Dalpozzo, R.; Bartoli, G.; Bencivenni, G. Chem. Soc. Rev. 2012, 41, 7247. (b) Ball-Jones, N. R.; Badillo, J. J.; Franz, A. K. Org. Biomol. Chem. 2012, 10, 5165. (c) Singh, G. S.; Desta, Z. Y. Chem. Rev. 2012, 112, 6104. (d) Hong, L.; Wang, R. Adv. Synth. Catal. 2013, 355, 1023. (e) Zhou, F.; Liu, Y.-L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381.

(6) (a) Corey, E. J.; Guzman-Perez, A. Angew. Chem., Int. Ed. 1998, 37, 388. (b) Douglas, C. J.; Overman, L. E. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5363. (c) Peterson, E. A.; Overman, L. E. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11943. (d) Trost, B. M.; Jiang, C. Synthesis 2006, 3, 369. (e) Bella, M.; Gasperi, T. Synthesis 2009, 10, 1583.

(7) Considering only C-3 all-carbon quaternary stereocenters, we omitted citing the nucleophilic additions to isatin derivatives, providing 3-substituted-3-hydroxyindolin-2-ones or 3-substituted-3-aminoindo-lin-2-ones.

(8) For recent examples of organocascades, see: (a) Bencivenni, G.; Wu, L.-Y.; Mazzanti, A.; Giannichi, B.; Pesciaioli, F.; Song, M.-P.; Bartoli, G.; Melchiorre, P. Angew. Chem., Int. Ed. 2009, 48, 7200. (b) Lan, Y.-B.; Zhao, H.; Liu, Z.-M.; Liu, G.-G.; Tao, J.-C.; Wang, X.-W. Org. Lett. 2011, 13, 4866. (c) Jiang, K.; Jia, Z.-J.; Chen, S.; Wu, L.; Chen, Y.-C. Chem. Eur. J. 2010, 16, 2852. (d) Jiang, K.; Jia, Z.-J.; Yin, X.; Wu, L.; Chen, Y.-C. Org. Lett. 2010, 12, 2766. (e) Huang, X.-F.; Liu, Z.-M.; Geng, Z.-C.; Zhang, S.-Y.; Wang, Y.; Wang, X.-W. Org. Biomol. Chem. 2012, 10, 8794. (f) Tan, B.; Candeias, N. R.; Barbas, C. F., III Nat. Chem. 2011, 3, 473. (g) Wei, Q.; Gong, L.-Z. Org. Lett. 2010, 12, 1008. (h) Chen, W.-B.; Wu, Z.-J.; Pei, Q.-L.; Cun, L.-F.; Zhang, X.-M.; Yuan, W.-C. Org. Lett. 2010, 12, 3132. (i) Cao, Y.; Jiang, X.; Liu, L.; Shen, F.; Zhang, F.; Wang, R. Angew. Chem., Int. Ed. 2011, 50, 9124. (j) Pesciaioli, F.; Righi, P.; Mazzanti, A.; Bartoli, G.; Bencivenni, G. Chem. Eur. J. 2011, 17, 2842. (k) Wei, W.-T.; Chen, C.-X.; Lu, R.-J.; Wang, J.-J.; Zhang, X.-J.; Yan, M. Org. Biomol. Chem. 2012, 10, 5245. (1) Duan, S.-W.; Li, Y.; Liu, Y.-Y.; Zou, Y.-Q.; Shi, D.-Q.; Xiao, W.-J. Chem. Commun. 2012, 48, 5160. (m) Jiang, X.; Sun, Y.; Yao, J.; Cao, Y.; Kai, M.; He, N.; Zhang, X.; Wang, Y.; Wang, R. Adv. Synth. Catal. 2012, 354, 917.

(9) For recent examples of organocatalyzed cycloadditions, see: (a) Jia, Z.-J.; Jiang, H.; Li, J.-L.; Gschwend, B.; Li, Q.-Z.; Yin, X.; Grouleff, J.; Chen, Y.-C.; Jørgensen, K. A. J. Am. Chem. Soc. **2011**, 133, 5053. (b) Liu, Y.; Nappi, M.; Arceo, E.; Vera, S.; Melchiorre, P. J. Am. Chem. Soc. **2011**, 133, 15212. (c) Voituriez, A.; Pinto, N.; Neel, M.; Retailleau, P.; Marinetti, A. Chem. Eur. J. **2010**, 16, 12541. (d) Tan, B.; Candeias, N. R.; Barbas, C. F., III J. Am. Chem. Soc. **2011**, 133, 4672. (e) Zhong, F.; Han, X.; Wang, Y.; Lu, Y. Angew. Chem., Int. Ed. **2011**, 50, 7837. (f) Tan, B.; Hernández-Torres, G.; Barbas, C. F., III J. Am. Chem. Soc. **2011**, 133, 12354. (g) Wang, L.-L.; Bai, J.-F.; Peng, L.; Qi, L.-W.; Jia, L.-N.; Guo, Y.-L.; Luo, X.-Y.; Xu, X.-Y.; Wang, L.-X. Chem. Commun. **2012**, 48, 5175. (h) Zhong, F.; Han, X.; Wang, Y.; Lu, Y. Chem. Sci. **2012**, 3, 1231.

(10) (a) Ohmatsu, K.; Kiyokawa, M.; Ooi, T. J. Am. Chem. Soc. 2011, 133, 1307. (b) Jiang, K.; Peng, J.; Cui, H.-L.; Chen, Y.-C. Chem. Commun. 2009, 3955. (c) Ogawa, S.; Shibata, N.; Inagaki, J.; Nakamura, S.; Toru, T.; Shiro, M. Angew. Chem., Int. Ed. 2007, 46, 8666. (d) Pesciaioli, F.; Righi, P.; Mazzanti, A.; Gianelli, C.; Mancinelli, M.; Bartoli, G.; Bencivenni, G. Adv. Synth. Catal. 2011, 353, 2953. (e) Liu, X.-L.; Liao, Y.-H.; Wu, Z.-J.; Cun, L.-F.; Zhang, X.-M.; Yuan, W.-C. J. Org. Chem. 2010, 75, 4872. (f) Tian, X.; Jiang, K.; Peng, J.; Du, W.; Chen, Y.-C. Org. Lett. 2008, 10, 3583. (g) He, R.; Ding, C.; Maruoka, K. Angew. Chem., Int. Ed. 2009, 48, 4559. (h) Cheng, L.; Liu, L.; Jia, H.; Wang, D.; Chen, Y.-J. J. Org. Chem. 2009, 74, 4650. (i) Li, X.; Xi, Z.-G.; Luo, S.; Cheng, J.-P. Org. Biomol. Chem. 2010, 8, 77. (j) Galzerano, P.; Bencivenni, G.; Pesciaioli, F.; Mazzanti, A.; Giannichi, B.; Sambri, L.; Bartoli, G.; Melchiorre, P. Chem. Eur. J. 2009, 15, 7846. (k) Li, X.; Luo, S.; Cheng, J.-P. Chem. Eur. J. 2010, 16, 14290. (1) Duan, S.-W.; An, J.; Chen, J.-R.; Xiao, W.-J. Org. Lett. 2011, 13, 2290. (m) He, R.; Shirakawa, S.; Maruoka, K. J. Am. Chem. Soc. 2009, 131, 16620. (n) Zhao, M.-X.; Tang, W.-H.; Chen, M.-X.; Wei, D.-K.; Dai, T.-L.; Shi, M. Eur. J. Org. Chem. 2011, 6078. (o) Zhang, T.; Cheng, L.; Hameed, S.; Liu, L.; Wang, D.; Chen, Y.-J. Chem. Commun. 2011, 47, 6644. (p) Pesciaioli, F.; Tian, X.; Bencivenni, G.; Bartoli, G.; Melchiorre, P. Synlett 2010, 11, 1704.

(11) (a) Wang, L.-L.; Peng, L.; Bai, J.-F.; Huang, Q.-C.; Xu, X.-Y.; Wang, L.-X. *Chem. Commun.* **2010**, *46*, 8064. (b) Peng, J.; Huang, X.; Jiang, L.; Cui, H.-L.; Chen, Y.-C. Org. Lett. **2011**, *13*, 4584.

(c) Companyó, X.; Zea, A.; Alba, A.-N. R.; Mazzanti, A.; Moyano, A.; Rios, R. Chem. Commun. 2010, 46, 6953. (d) Noole, A.; Osĕka, M.; Pehk, T.; Öeren, M.; Järving, I.; Elsegood, M. R. J.; Malkov, A. V.; Lopp, M.; Kanger, T. Adv. Synth. Catal. 2013, 355, 829. (e) Li, Y.-M.; Li, X.; Peng, F.-Z.; Li, Z.-Q.; Wu, S.-T.; Sun, Z.-W.; Zhang, H.-B.; Shao, Z.-H. Org. Lett. 2011, 13, 6200. (f) Sun, W.; Zhu, G.; Wu, C.; Hong, L.; Wang, R. Chem. Eur. J. 2012, 18, 6737. (g) Albertshofer, K.; Tan, B.; Barbas, C. F., III Org. Lett. 2012, 14, 1834. (h) Albertshofer, K.; Tan, B.; Barbas, C. F., III Org. Lett. 2012, 14, 5968. See also ref 8f.

(12) In ref 10 we cited papers where intermolecular additions exploit oxindoles as Michael donors. An alternative route to construct the C-3 quaternary stereocenter is possible, by using alkylidene oxindoles as Michael acceptors. However, almost all of the reported examples describe nucleophilic additions directly to the C-3 position, the regioselectivity being determined by the highest electron-withdrawing power on the β terminus of the double bond: (a) Liu, L.; Wu, D.; Zheng, S.; Li, T.; Li, X.; Wang, S.; Li, J.; Li, H.; Wang, W. Org. Lett. **2012**, *14*, 134. (b) Liu, L.; Wu, D.; Li, X.; Wang, S.; Li, H.; Li, J.; Wang, W. Chem. Commun. **2012**, *48*, 1692. (c) Guo, C.; Song, J.; Huang, J.-Z.; Chen, P.-H.; Luo, S.-W.; Gong, L.-Z. Angew. Chem., Int. Ed. **2012**, *51*, 1046. (d) Zhao, H.; Lan, Y.-B.; Liu, Z.-M.; Wang, Y.; Wang, X.-W.; Tao, J.-C. Eur. J. Org. Chem. **2012**, 1935. (e) Peng, J.; Huang, X.; Cui, H.-L.; Chen, Y.-C. Org. Lett. **2010**, *12*, 4260.

(13) Duan, S.-W.; Lu, H.-H.; Zhang, F.-G.; Xuan, J.; Chen, J.-R.; Xiao, W.-J. Synthesis 2011, 1847.

(14) (a) Chiarucci, M.; Lombardo, M.; Trombini, C.; Quintavalla, A. *Adv. Synth. Catal.* **2012**, 354, 364. (b) Quintavalla, A.; Lombardo, M.; Sanap, S. P.; Trombini, C. *Adv. Synth. Catal.* **2013**, 355, 938.

(15) (a) Doyle, A. G.; Jacobsen, E. N. Chem. Rev. 2007, 107, 5713.
(b) Yeboah, E. M. O.; Yeboah, S. O.; Singh, G. S. Tetrahedron 2011, 1725. (c) Marcelli, T.; Hiemstra, H. Synthesis 2010, 8, 1229. (d) Tian, S.-K.; Chen, Y.; Hang, J.; Tang, L.; Mcdaid, P.; Deng, L. Acc. Chem. Res. 2004, 37, 621.

(16) (a) O'Connor, C. J.; Beckmann, H. S. G.; Spring, D. R. Chem. Soc. Rev. 2012, 41, 4444. (b) Burke, M. D.; Schreiber, S. L. Angew. Chem., Int. Ed. 2004, 43, 46. (c) Spandl, R. J.; Bender, A.; Spring, D. R. Org. Biomol. Chem. 2008, 6, 1149.

(17) Bordwell, F. G.; Fried, H. E. J. Org. Chem. 1991, 56, 4218.

(18) The temperature effect on the diastereoselectivity was investigated also on substrate **2b**. When the model reaction was performed at -20 °C, the conversion was complete in 14 h but the dr was still 1/1. The same reaction at -40 °C did not proceed.

(19) (a) Okino, T.; Hoashi, Y.; Furukawa, T.; Xu, X.; Takemoto, Y. J. Am. Chem. Soc. **2005**, 127, 119. (b) Li, H.; Wang, Y.; Tang, L.; Wu, F.; Liu, X.; Guo, C.; Foxman, B. M.; Deng, L. Angew. Chem., Int. Ed. **2005**, 44, 105. (c) Hamza, A.; Schubert, G.; Soós, T.; Pápai, I. J. Am. Chem. Soc. **2006**, 128, 13151. (d) Marcelli, T. Wiley Interdiscip. Rev.: Comput. Mol. Sci. **2011**, 1, 142.

(20) Liao, Y.-H.; Liu, X.-L.; Wu, Z.-J.; Cun, L.-F.; Zhang, X.-M.; Yuan, W.-C. Org. Lett. **2010**, *12*, 2896.

(21) (a) Zhu, Q.; Lu, Y. Angew. Chem., Int. Ed. 2010, 49, 7753. (b) Lee, H. J.; Kang, S. H.; Kim, D. Y. Synlett 2011, 1559.

(22) (a) Li, X.; Li, Y.-M.; Peng, F.-Z.; Wu, S.-T.; Li, Z.-Q.; Sun, Z.-W.;
Zhang, H.-B.; Shao, Z.-H. Org. Lett. 2011, 13, 6160. (b) Bui, T.; Syed, S.;
Barbas, C. F., III J. Am. Chem. Soc. 2009, 131, 8758. (c) Li, X.; Zhang, B.;
Xi, Z.-G.; Luo, S.; Cheng, J.-P. Adv. Synth. Catal. 2010, 352, 416.
(d) Ding, M.; Zhou, F.; Liu, Y.-L.; Wang, C.-H.; Zhao, X.-L.; Zhou, J.
Chem. Sci. 2011, 2, 2035. (e) Liu, X.-L.; Wu, Z.-J.; Du, X.-L.; Zhang, X.-M.; Yuan, W.-C. J. Org. Chem. 2011, 76, 4008.

(23) For examples of Pd-promoted synthesis of hydroxylamines from nitro compounds, see: (a) Han, B.; Liu, Q.-P.; Li, R.; Tian, X.; Xiong, X.-F.; Deng, J.-G.; Chen, Y.-C. Chem. Eur. J. 2008, 14, 8094. (b) Takenaka, Y.; Kiyosu, T.; Choi, J.-C.; Sakakura, T.; Yasuda, H. ChemSusChem 2010, 3, 1166. (c) Wurz, R. P.; Charette, A. B. J. Org. Chem. 2004, 69, 1262. (24) (a) Anthoni, U.; Christophersen, C.; Nielsen, P. H. Alkaloids: Chemical and Biological Perspectives; Elsevier Science: Oxford, U.K., 1999; p 163. (b) Takano, S.; Ogasawara, K. The Alkaloids; Academic Press: San Diego, CA, 1989; p 225. (c) Kawasaki, T.; Shinada, M.;

Ohzono, M.; Ogawa, A.; Terashima, R.; Sakamoto, M. J. Org. Chem. 2008, 73, 5959.

(25) The Raney nickel promoted reduction of *syn*-**4b** afforded (*S*)-*tert*butyl 3-((2*R*,3*R*)-3-amino-1-ethoxy-1-oxobutan-2-yl)-2-oxoindoline-1carboxylate (**15**) as a single stereoisomer.

(26) Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. Org. Lett. 2005, 7, 1967.

(27) Malhotra, S.; Balwani, S.; Dhawan, A.; Singh, B. K.; Kumar, S.; Thimmulappa, R.; Biswal, S.; Olsen, C. E.; Van der Eycken, E.; Prasad, A. K.; Ghosh, B.; Parmar, V. S. *Med. Chem. Commun.* **2011**, *2*, 743.

(28) Cao, S.-H.; Zhang, X.-C.; Wei, Y.; Shi, M. Eur. J. Org. Chem. 2011, 2668.

(29) Kodukulla, R. P. K.; Trivedi, G. K.; Vora, J. D.; Mathur, H. H. Synth. Commun. 1994, 24, 819.